1
|
Maroni G, Tomassi E, Valenti D, Fernàndez-Busquets X, Pucci L, Levantini E, Caddeo C. Pegylated-liposomes increase the efficacy of Idelalisib in lymphoma B-cells. Int J Pharm 2024:124144. [PMID: 38653342 DOI: 10.1016/j.ijpharm.2024.124144] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/20/2024] [Revised: 04/05/2024] [Accepted: 04/20/2024] [Indexed: 04/25/2024]
Abstract
New drugs and technologies are continuously developed to improve the efficacy and minimize the critical side effects of cancer treatments. The present investigation focuses on the development of a liposomal formulation for Idelalisib, a small-molecule kinase inhibitor approved for the treatment of lymphoid malignancies. Idelalisib is a potent and selective antitumor agent, but it is not indicated nor recommended for first-line treatment due to fatal and serious toxicities. Herein, liposomes are proposed as a delivery tool to improve the therapeutic profile of Idelalisib. Specifically, PEGylated liposomes were prepared, and their physicochemical and technological features were investigated. Light-scattering spectroscopy and cryo-transmission electron microscopy revealed nanosized unilamellar vesicles, which were proved to be stable in storage and in simulated biological fluids. The cytotoxicity of the liposome formulation was investigated in a human non-Hodgkin's lymphoma B cell line. Idelalisib was able to induce death of tumor cells if delivered by the nanocarrier system at increased efficacy. These findings suggest that combining Idelalisib and nanotechnologies may be a powerful strategy to increase the antitumor efficacy of the drug.
Collapse
Affiliation(s)
- Giorgia Maroni
- Institute of Biomedical Technologies, Italian National Research Council, Via Moruzzi 1, 56124 Pisa, Italy
| | - Elena Tomassi
- Institute of Agricultural Biology and Biotechnology, Italian National Research Council, Via Moruzzi 1, 56124 Pisa, Italy
| | - Donatella Valenti
- Nanomalaria Group, Institute for Bioengineering of Catalonia (IBEC), The Barcelona Institute of Science and Technology, Baldiri Reixac 10-12, Barcelona E08028, Spain
| | - Xavier Fernàndez-Busquets
- Nanomalaria Group, Institute for Bioengineering of Catalonia (IBEC), The Barcelona Institute of Science and Technology, Baldiri Reixac 10-12, Barcelona E08028, Spain; Barcelona Institute for Global Health (ISGlobal), Hospital Clínic-Universitat de Barcelona, Rossellό 149-153, Barcelona E08036, Spain
| | - Laura Pucci
- Institute of Agricultural Biology and Biotechnology, Italian National Research Council, Via Moruzzi 1, 56124 Pisa, Italy
| | - Elena Levantini
- Institute of Biomedical Technologies, Italian National Research Council, Via Moruzzi 1, 56124 Pisa, Italy
| | - Carla Caddeo
- Dept. of Scienze della Vita e dell'Ambiente, Sezione di Scienze del Farmaco, University of Cagliari, S.P. Monserrato-Sestu Km 0.700, 09042 Monserrato, (Cagliari), Italy.
| |
Collapse
|
2
|
Antinori A, Vergori A, Ripamonti D, Valenti D, Esposito V, Carleo MA, Rusconi S, Cascio A, Manzillo E, Andreoni M, Orofino G, Cappuccio A, Reale L, Marini MG, Mancusi D, Termini R, Uglietti A, Portaro M. Investigating coping and stigma in people living with HIV through narrative medicine in the Italian multicentre non-interventional study DIAMANTE. Sci Rep 2023; 13:17624. [PMID: 37848464 PMCID: PMC10582167 DOI: 10.1038/s41598-023-44768-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/05/2023] [Accepted: 10/12/2023] [Indexed: 10/19/2023] Open
Abstract
Antiretroviral therapy (ART) significantly reduced Human Immunodeficiency Virus (HIV) morbidity and mortality; nevertheless, stigma still characterises the living with this condition. This study explored patients' coping experience by integrating narrative medicine (NM) in a non-interventional clinical trial. From June 2018 to September 2020 the study involved 18 centres across Italy; enrolled patients were both D/C/F/TAF naïve and previously ART-treated. Narratives were collected at enrolment (V1) and last visit (V4) and then independently analysed by three NM specialist researchers through content analysis. One-hundred and fourteen patients completed both V1 and V4 narratives. Supportive relationships with clinicians and undetectable viral load facilitated coping. Conversely, lack of disclosure of HIV-positive status, HIV metaphors, and unwillingness to narrate the life before the diagnosis indicated internalised stigma. This is the first non-interventional study to include narratives as patient reported outcomes (PROs). Improving HIV awareness and reducing the sense of guilt experienced by patients helps to overcome stigma and foster coping.
Collapse
Affiliation(s)
- A Antinori
- HIV/AIDS Unit, National Institute for Infectious Diseases "Lazzaro Spallanzani" IRCCS, Rome, Italy
| | - A Vergori
- HIV/AIDS Unit, National Institute for Infectious Diseases "Lazzaro Spallanzani" IRCCS, Rome, Italy
| | - D Ripamonti
- Infectious Diseases Clinic, Papa Giovanni XXIII Hospital, Bergamo, Italy
| | - D Valenti
- Infectious Diseases Clinic, Papa Giovanni XXIII Hospital, Bergamo, Italy
| | - V Esposito
- General Infectious Diseases Unit, Department of Infectious Disease and Infectious Emergencies, Cotugno Hospital, Naples, Italy
| | - M A Carleo
- General Infectious Diseases Unit, Department of Infectious Disease and Infectious Emergencies, Cotugno Hospital, Naples, Italy
| | - S Rusconi
- DIBIC Luigi Sacco, University of Milan, Milan, Italy
- Infectious Diseases Unit, Legnano Hospital ASST Ovest Milanese, Legnano, Italy
| | - A Cascio
- Infectious Diseases Clinic, AOU Policlinico "P.Giaccone", Palermo, Italy
| | - E Manzillo
- Infectious Disease and Infectious Emergencies, Azienda Ospedaliera dei Colli, Naples, Italy
| | - M Andreoni
- Infectious Diseases Clinic, Foundation Policlinico Tor Vergata University Hospital, Rome, Italy
| | - G Orofino
- Amedeo di Savoia Hospital Unit of Infectious Diseases Torino, Turin, Italy
| | | | - L Reale
- Healthcare Area, ISTUD Srl, Milan, Italy
| | - M G Marini
- Healthcare Area, ISTUD Srl, Milan, Italy
| | - D Mancusi
- Medical Affairs Department, Infectious Diseases and Vaccines, Janssen-Cilag SpA, Via Michelangelo Buonarroti, 23, 20093, Cologno Monzese, MI, Italy
| | - R Termini
- Medical Affairs Department, Infectious Diseases and Vaccines, Janssen-Cilag SpA, Via Michelangelo Buonarroti, 23, 20093, Cologno Monzese, MI, Italy
| | - A Uglietti
- Medical Affairs Department, Infectious Diseases and Vaccines, Janssen-Cilag SpA, Via Michelangelo Buonarroti, 23, 20093, Cologno Monzese, MI, Italy
| | - M Portaro
- Medical Affairs Department, Infectious Diseases and Vaccines, Janssen-Cilag SpA, Via Michelangelo Buonarroti, 23, 20093, Cologno Monzese, MI, Italy.
| |
Collapse
|
3
|
Casula L, Pireddu R, Cardia MC, Pini E, Valenti D, Schlich M, Sinico C, Marceddu S, Dragićević N, Fadda AM, Lai F. Nanosuspension-Based Dissolvable Microneedle Arrays to Enhance Diclofenac Skin Delivery. Pharmaceutics 2023; 15:2308. [PMID: 37765277 PMCID: PMC10536216 DOI: 10.3390/pharmaceutics15092308] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/14/2023] [Revised: 08/30/2023] [Accepted: 09/07/2023] [Indexed: 09/29/2023] Open
Abstract
Applying a formulation on the skin represents a patient-acceptable and therapeutically effective way to administer drugs locally and systemically. However, the stratum corneum stands as an impermeable barrier that only allows a very limited number of drugs to be distributed in the underlying tissues, limiting the feasibility of this administration route. Microneedle arrays are minimally invasive platforms that allow the delivery of drugs within/across the skin through the temporary mechanical disruption of the stratum corneum. In this work, microneedle arrays were combined with nanosuspensions, a technology for solubility enhancement of water insoluble molecules, for the skin delivery of diclofenac. Nanosuspensions were prepared using a top-down method and loaded in the tips of 500 µm or 800 µm high microneedles. The quality of the combined platform was assessed using electron microscopy and spectroscopic and calorimetry techniques, demonstrating the ability to load high amounts of the hydrophobic drug and the compatibility between excipients. Lastly, the application of nanosuspension-loaded microneedles on the skin in vitro allowed the delivery of diclofenac within and across the stratum corneum, proving the potential of this combination to enhance skin delivery of scarcely soluble drugs.
Collapse
Affiliation(s)
- Luca Casula
- Dipartimento di Scienze della Vita e dell'Ambiente, Sezione di Scienze del Farmaco, CNBS, Università degli Studi di Cagliari, 09124 Cagliari, Italy
| | - Rosa Pireddu
- Dipartimento di Scienze della Vita e dell'Ambiente, Sezione di Scienze del Farmaco, CNBS, Università degli Studi di Cagliari, 09124 Cagliari, Italy
| | - Maria Cristina Cardia
- Dipartimento di Scienze della Vita e dell'Ambiente, Sezione di Scienze del Farmaco, CNBS, Università degli Studi di Cagliari, 09124 Cagliari, Italy
| | - Elena Pini
- Department of Pharmaceutical Sciences, General and Organic Chemistry Section "Alessandro Marchesini", University of Milan, 20133 Milan, Italy
| | - Donatella Valenti
- Dipartimento di Scienze della Vita e dell'Ambiente, Sezione di Scienze del Farmaco, CNBS, Università degli Studi di Cagliari, 09124 Cagliari, Italy
| | - Michele Schlich
- Dipartimento di Scienze della Vita e dell'Ambiente, Sezione di Scienze del Farmaco, CNBS, Università degli Studi di Cagliari, 09124 Cagliari, Italy
| | - Chiara Sinico
- Dipartimento di Scienze della Vita e dell'Ambiente, Sezione di Scienze del Farmaco, CNBS, Università degli Studi di Cagliari, 09124 Cagliari, Italy
| | - Salvatore Marceddu
- Istituto di Scienze delle Produzioni Alimentari (ISPA)-CNR, Sez. di Sassari, 07040 Baldinca, Italy
| | - Nina Dragićević
- Department of Pharmacy, Singidunum University, 11107 Belgrade, Serbia
| | - Anna Maria Fadda
- Dipartimento di Scienze della Vita e dell'Ambiente, Sezione di Scienze del Farmaco, CNBS, Università degli Studi di Cagliari, 09124 Cagliari, Italy
| | - Francesco Lai
- Dipartimento di Scienze della Vita e dell'Ambiente, Sezione di Scienze del Farmaco, CNBS, Università degli Studi di Cagliari, 09124 Cagliari, Italy
| |
Collapse
|
4
|
Caddeo C, Miglionico R, Rinaldi R, Nigro I, Lamorte D, Chiummiento L, Lupattelli P, Funicello M, D’Orsi R, Valenti D, Santoro V, Fadda AM, Bisaccia F, Vassallo A, Armentano MF. PEGylated Liposomes Loaded with Carbamate Inhibitor ANP0903 Trigger Apoptosis by Enhancing ER Stress in HepG2 Cancer Cells. Int J Mol Sci 2023; 24:ijms24054552. [PMID: 36901980 PMCID: PMC10002784 DOI: 10.3390/ijms24054552] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/01/2023] [Revised: 02/22/2023] [Accepted: 02/23/2023] [Indexed: 03/03/2023] Open
Abstract
Liver cancer is one of the most common causes of cancer death worldwide. In recent years, substantial progress has been made in the development of systemic therapies, but there is still the need for new drugs and technologies that can increase the survival and quality of life of patients. The present investigation reports the development of a liposomal formulation of a carbamate molecule, reported as ANP0903, previously tested as an inhibitor of HIV-1 protease and now evaluated for its ability to induce cytotoxicity in hepatocellular carcinoma cell lines. PEGylated liposomes were prepared and characterized. Small, oligolamellar vesicles were produced, as demonstrated by light scattering results and TEM images. The physical stability of the vesicles in biological fluids was demonstrated in vitro, alongside the stability during storage. An enhanced cellular uptake was verified in HepG2 cells treated with liposomal ANP0903, resulting in a greater cytotoxicity. Several biological assays were performed to elucidate the molecular mechanisms explaining the proapoptotic effect of ANP0903. Our results allow us to hypothesize that the cytotoxic action in tumor cells is probably due to the inhibition of the proteasome, resulting in an increase in the amount of ubiquitinated proteins within the cells, which in turn triggers activation of autophagy and apoptosis processes, resulting in cell death. The proposed liposomal formulation represents a promising approach to deliver a novel antitumor agent to cancer cells and enhance its activity.
Collapse
Affiliation(s)
- Carla Caddeo
- Department of Scienze della Vita e dell’Ambiente, Sezione di Scienze del Farmaco, University of Cagliari, Via Ospedale 72, 09124 Cagliari, Italy
| | - Rocchina Miglionico
- Department of Scienze, University of Basilicata, Viale dell’Ateneo Lucano 10, 85100 Potenza, Italy
| | - Roberta Rinaldi
- Department of Scienze, University of Basilicata, Viale dell’Ateneo Lucano 10, 85100 Potenza, Italy
| | - Ilaria Nigro
- Department of Scienze, University of Basilicata, Viale dell’Ateneo Lucano 10, 85100 Potenza, Italy
| | - Daniela Lamorte
- Laboratory of Preclinical and Translational Research, Centro di Riferimento Oncologico della Basilicata (IRCCS-CROB), 85028 Rionero in Vulture, Italy
| | - Lucia Chiummiento
- Department of Scienze, University of Basilicata, Viale dell’Ateneo Lucano 10, 85100 Potenza, Italy
| | - Paolo Lupattelli
- Department of Chimica, Sapienza University of Roma, p.le Aldo Moro 5, 00185 Roma, Italy
| | - Maria Funicello
- Department of Scienze, University of Basilicata, Viale dell’Ateneo Lucano 10, 85100 Potenza, Italy
| | - Rosarita D’Orsi
- Department of Scienze, University of Basilicata, Viale dell’Ateneo Lucano 10, 85100 Potenza, Italy
| | - Donatella Valenti
- Department of Scienze della Vita e dell’Ambiente, Sezione di Scienze del Farmaco, University of Cagliari, Via Ospedale 72, 09124 Cagliari, Italy
| | - Valentina Santoro
- Department of Farmacia, University of Salerno, Via Giovanni Paolo II 132, 84084 Salerno, Italy
| | - Anna Maria Fadda
- Department of Scienze della Vita e dell’Ambiente, Sezione di Scienze del Farmaco, University of Cagliari, Via Ospedale 72, 09124 Cagliari, Italy
| | - Faustino Bisaccia
- Department of Scienze, University of Basilicata, Viale dell’Ateneo Lucano 10, 85100 Potenza, Italy
| | - Antonio Vassallo
- Department of Scienze, University of Basilicata, Viale dell’Ateneo Lucano 10, 85100 Potenza, Italy
- Spinoff TNcKILLERS s.r.l., Viale dell’Ateneo Lucano 10, 85100 Potenza, Italy
- Correspondence: ; Tel.: +39-0971205624
| | | |
Collapse
|
5
|
Grimaudo R, de Castro ASM, Messina A, Solano E, Valenti D. Quantum Phase Transitions for an Integrable Quantum Rabi-like Model with Two Interacting Qubits. Phys Rev Lett 2023; 130:043602. [PMID: 36763445 DOI: 10.1103/physrevlett.130.043602] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/11/2022] [Revised: 12/13/2022] [Accepted: 12/22/2022] [Indexed: 06/18/2023]
Abstract
A two-interacting-qubit quantum Rabi-like model with vanishing transverse fields on the qubit pair is studied. Independently of the coupling regime, this model can be exactly and unitarily reduced to two independent single-spin quantum Rabi models, where the spin-spin coupling plays the role of the transverse field. This transformation and the analytical treatment of the single-spin quantum Rabi model provide the key to prove the integrability of our model. The existence of different first-order quantum phase transitions, characterized by discontinuous two-spin magnetization, mean photon number, and concurrence, is brought to light.
Collapse
Affiliation(s)
- R Grimaudo
- Department of Physics and Chemistry "Emilio Segrè", University of Palermo, viale delle Scienze, Building 18, I-90128, Palermo, Italy
| | - A S Magalhães de Castro
- Universidade Estadual de Ponta Grossa, Departamento de Física, CEP 84030-900, Ponta Grossa, Paraná state, Brazil
| | - A Messina
- Department of Mathematics and Informatics, University of Palermo, Via Archirafi 34, I-90123 Palermo, Italy
| | - E Solano
- International Center of Quantum Artificial Intelligence for Science and Technology (QuArtist) and Physics Department, Shanghai University, 200444 Shanghai, China
- IKERBASQUE, Basque Foundation for Science, Plaza Euskadi 5, 48009 Bilbao, Spain
- Kipu Quantum, Greifswalderstrasse 226, 10405 Berlin, Germany
| | - D Valenti
- Department of Physics and Chemistry "Emilio Segrè", University of Palermo, viale delle Scienze, Building 18, I-90128, Palermo, Italy
| |
Collapse
|
6
|
Korenblik R, Olij B, Aldrighetti LA, Hilal MA, Ahle M, Arslan B, van Baardewijk LJ, Baclija I, Bent C, Bertrand CL, Björnsson B, de Boer MT, de Boer SW, Bokkers RPH, Rinkes IHMB, Breitenstein S, Bruijnen RCG, Bruners P, Büchler MW, Camacho JC, Cappelli A, Carling U, Chan BKY, Chang DH, Choi J, Font JC, Crawford M, Croagh D, Cugat E, Davis R, De Boo DW, De Cobelli F, De Wispelaere JF, van Delden OM, Delle M, Detry O, Díaz-Nieto R, Dili A, Erdmann JI, Fisher O, Fondevila C, Fretland Å, Borobia FG, Gelabert A, Gérard L, Giuliante F, Gobardhan PD, Gómez F, Grünberger T, Grünhagen DJ, Guitart J, Hagendoorn J, Heil J, Heise D, Herrero E, Hess GF, Hoffmann MH, Iezzi R, Imani F, Nguyen J, Jovine E, Kalff JC, Kazemier G, Kingham TP, Kleeff J, Kollmar O, Leclercq WKG, Ben SL, Lucidi V, MacDonald A, Madoff DC, Manekeller S, Martel G, Mehrabi A, Mehrzad H, Meijerink MR, Menon K, Metrakos P, Meyer C, Moelker A, Modi S, Montanari N, Navines J, Neumann UP, Peddu P, Primrose JN, Qu X, Raptis D, Ratti F, Ridouani F, Rogan C, Ronellenfitsch U, Ryan S, Sallemi C, Moragues JS, Sandström P, Sarriá L, Schnitzbauer A, Serenari M, Serrablo A, Smits MLJ, Sparrelid E, Spüntrup E, Stavrou GA, Sutcliffe RP, Tancredi I, Tasse JC, Udupa V, Valenti D, Fundora Y, Vogl TJ, Wang X, White SA, Wohlgemuth WA, Yu D, Zijlstra IAJ, Binkert CA, Bemelmans MHA, van der Leij C, Schadde E, van Dam RM. Dragon 1 Protocol Manuscript: Training, Accreditation, Implementation and Safety Evaluation of Portal and Hepatic Vein Embolization (PVE/HVE) to Accelerate Future Liver Remnant (FLR) Hypertrophy. Cardiovasc Intervent Radiol 2022; 45:1391-1398. [PMID: 35790566 PMCID: PMC9458562 DOI: 10.1007/s00270-022-03176-1] [Citation(s) in RCA: 11] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/29/2021] [Accepted: 05/08/2022] [Indexed: 12/02/2022]
Abstract
STUDY PURPOSE The DRAGON 1 trial aims to assess training, implementation, safety and feasibility of combined portal- and hepatic-vein embolization (PVE/HVE) to accelerate future liver remnant (FLR) hypertrophy in patients with borderline resectable colorectal cancer liver metastases. METHODS The DRAGON 1 trial is a worldwide multicenter prospective single arm trial. The primary endpoint is a composite of the safety of PVE/HVE, 90-day mortality, and one year accrual monitoring of each participating center. Secondary endpoints include: feasibility of resection, the used PVE and HVE techniques, FLR-hypertrophy, liver function (subset of centers), overall survival, and disease-free survival. All complications after the PVE/HVE procedure are documented. Liver volumes will be measured at week 1 and if applicable at week 3 and 6 after PVE/HVE and follow-up visits will be held at 1, 3, 6, and 12 months after the resection. RESULTS Not applicable. CONCLUSION DRAGON 1 is a prospective trial to assess the safety and feasibility of PVE/HVE. Participating study centers will be trained, and procedures standardized using Work Instructions (WI) to prepare for the DRAGON 2 randomized controlled trial. Outcomes should reveal the accrual potential of centers, safety profile of combined PVE/HVE and the effect of FLR-hypertrophy induction by PVE/HVE in patients with CRLM and a small FLR. TRIAL REGISTRATION Clinicaltrials.gov: NCT04272931 (February 17, 2020). Toestingonline.nl: NL71535.068.19 (September 20, 2019).
Collapse
Affiliation(s)
- R Korenblik
- GROW School for Oncology and Developmental Biology, Maastricht University, Maastricht Universiteitssingel 40 room 5.452, 6229 ET, Maastricht, The Netherlands.
- Department of Surgery, Maastricht University Medical Center, Maastricht, The Netherlands.
| | - B Olij
- GROW School for Oncology and Developmental Biology, Maastricht University, Maastricht Universiteitssingel 40 room 5.452, 6229 ET, Maastricht, The Netherlands
- Department of Surgery, Maastricht University Medical Center, Maastricht, The Netherlands
| | | | - M Abu Hilal
- Department of Surgery, Fondazione Poliambulanza, Brescia, Italy
| | - M Ahle
- Deparment of Radiology, University Hospital, Linköping, Sweden
| | - B Arslan
- Department of Radiology, Rush University Medical Center, Chicago, USA
| | - L J van Baardewijk
- Department of Radiology, Maxima Medisch Centrum, Eindhoven, The Netherlands
| | - I Baclija
- Department of Radiology, Clinic Favoriten, Vienna, Austria
| | - C Bent
- Department of Radiology, Bournemouth and Christuchurch, The Royal Bournemouth and Christchurch Hospitals, Bournemouth and Christuchurch, UK
| | - C L Bertrand
- Department of Surgery, CHU UCLouvain Namur, Namur, Belgium
| | - B Björnsson
- Department of Surgery, Biomedical and Clinical Sciences, Linköping University Hospital, Linköping, Sweden
| | - M T de Boer
- Department of Surgery, University Medical Center Groningen, Groningen, The Netherlands
| | - S W de Boer
- Deparment of Radiology and Nuclear Medicine, Maastricht University Medical Center, Maastricht, The Netherlands
| | - R P H Bokkers
- Department of Radiology, University Medical Center Groningen, Groningen, The Netherlands
| | - I H M Borel Rinkes
- Department of Surgery, University Medical Center Utrecht, Utrecht, The Netherlands
| | - S Breitenstein
- Department of General and Visceral Surgery, Cantonal Hospital Winterthur, Winterthur, Switzerland
| | - R C G Bruijnen
- Department of Radiology, University Medical Center Utrecht, Utrecht, The Netherlands
| | - P Bruners
- Department of Radiology, University Hospital Aachen, Aachen, Germany
| | - M W Büchler
- Department of Surgery, University Hospital Heidelberg, Heidelberg, Germany
| | - J C Camacho
- Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, USA
| | - A Cappelli
- Department of Radiology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Sant'Orsola-Malpighi Hospital, Bologna, Italy
| | - U Carling
- Department of Radiology, University Hospital Oslo, Oslo, Norway
| | - B K Y Chan
- Department of Surgery, Aintree University Hospitals NHS, Liverpool, UK
| | - D H Chang
- Department of Radiology, University Hospital Heidelberg, Heidelberg, Germany
| | - J Choi
- Department of Surgery, Western Health Footscray, Footscray, Australia
| | - J Codina Font
- Department of Radiology, University Hospital Dr. Josep Trueta de Girona, Girona, Spain
| | - M Crawford
- Department of Surgery, Royal Prince Alfred Hospital, Camperdown, Australia
| | - D Croagh
- Department of Surgery, Monash Health, Clayton, Australia
| | - E Cugat
- Department of Surgery, University Hospital Germans Trias I Pujol, Badalona, Spain
| | - R Davis
- Department of Radiology, Aintree University Hospitals NHS, Liverpool, UK
| | - D W De Boo
- Department of Radiology, Monash Health, Clayton, Australia
| | - F De Cobelli
- Department of Radiology, Ospedale San Raffaele, Milan, Italy
| | | | - O M van Delden
- Department of Radiology, Amsterdam University Medical Centers Location AMC, Amsterdam, The Netherlands
| | - M Delle
- Department of Radiology, Karolinska University Hospital, Stockholm, Sweden
| | - O Detry
- Department of Surgery, CHU de Liège, Liège, Belgium
| | - R Díaz-Nieto
- Department of Surgery, Aintree University Hospitals NHS, Liverpool, UK
| | - A Dili
- Department of Surgery, CHU UCLouvain Namur, Namur, Belgium
| | - J I Erdmann
- Department of Surgery, Amsterdam University Medical Centers Location AMC, Amsterdam, The Netherlands
| | - O Fisher
- Department of Surgery, Royal Prince Alfred Hospital, Camperdown, Australia
| | - C Fondevila
- Department of Surgery, Hospital Clínic de Barcelona, Barcelona, Spain
| | - Å Fretland
- Department of Surgery, University Hospital Oslo, Oslo, Norway
| | - F Garcia Borobia
- Department of Surgery, Hospital Parc Taulí de Sabadell, Sabadell, Spain
| | - A Gelabert
- Department of Radiology, Hospital Parc Taulí de Sabadell, Sabadell, Spain
- Department of Radiology, University Hospital Mútua Terassa, Terassa, Spain
| | - L Gérard
- Department of Radiology, CHU de Liège, Liège, Belgium
| | - F Giuliante
- Department of Surgery, Gemelli University Hospital Rome, Rome, Italy
| | - P D Gobardhan
- Department of Surgery, Amphia, Breda, The Netherlands
| | - F Gómez
- Department of Radiology, Hospital Clínic de Barcelona, Barcelona, Spain
| | - T Grünberger
- Department of Surgery, HPB Center Vienna Health Network, Clinic Favoriten, Vienna, Austria
| | - D J Grünhagen
- Department of Surgery, Erasmus Medisch Centrum, Rotterdam, The Netherlands
| | - J Guitart
- Department of Radiology, University Hospital Mútua Terassa, Terassa, Spain
| | - J Hagendoorn
- Department of Surgery, University Medical Center Utrecht, Utrecht, The Netherlands
| | - J Heil
- Department of Surgery, University Hospital Frankfurt, Frankfurt, Germany
| | - D Heise
- Department of General, Visceral and Transplant Surgery, University Hospital Aachen, Aachen, Germany
| | - E Herrero
- Department of Surgery, University Hospital Mútua Terassa, Terassa, Spain
| | - G F Hess
- Department of Surgery, Clarunis University Hospital, Basel, Switzerland
| | - M H Hoffmann
- Department of Radiology, St. Clara Spital, Basel, Switzerland
| | - R Iezzi
- Department of Radiology, Gemelli University Hospital, Rome, Italy
| | - F Imani
- Department of Radiology, Amphia, Breda, The Netherlands
| | - J Nguyen
- Department of Radiology, Western Health Footscray, Footscray, Australia
| | - E Jovine
- Department of Surgery, Ospedale Maggiore di Bologna, Bologna, Italy
| | - J C Kalff
- Department of Surgery, University Hospital Bonn, Bonn, Germany
| | - G Kazemier
- Department of Surgery, Amsterdam University Medical Centers Location VU, Amsterdam, The Netherlands
| | - T P Kingham
- Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, USA
| | - J Kleeff
- Department of Surgery, University Hospital Halle (Saale), Halle, Germany
| | - O Kollmar
- Department of Surgery, Clarunis University Hospital, Basel, Switzerland
| | - W K G Leclercq
- Department of Surgery, Maxima Medisch Centrum, Eindhoven, The Netherlands
| | - S Lopez Ben
- Department of Surgery, University Hospital Dr. Josep Trueta de Girona, Girona, Spain
| | - V Lucidi
- Department of Surgery, Hôpital Erasme, Brussels, Belgium
| | - A MacDonald
- Department of Radiology, Oxford University Hospital NHS, Oxford, UK
| | - D C Madoff
- Department of Radiology, Yale School of Medicine, New Haven, USA
| | - S Manekeller
- Department of Surgery, University Hospital Bonn, Bonn, Germany
| | - G Martel
- Department of Surgery, The Ottawa Hospital, Ottawa, Canada
| | - A Mehrabi
- Department of Surgery, University Hospital Heidelberg, Heidelberg, Germany
| | - H Mehrzad
- Department of Radiology, Queen Elizabeth Hospital Birmingham NHS, Birmingham, UK
| | - M R Meijerink
- Department of Radiology, Amsterdam University Medical Centers Location VU, Amsterdam, The Netherlands
| | - K Menon
- Department of Surgery, King's College Hospital NHS, London, UK
| | - P Metrakos
- Department of Surgery, McGill University Health Centre, Montréal, Canada
| | - C Meyer
- Department of Radiology, University Hospital Bonn, Bonn, Germany
| | - A Moelker
- Department of Radiology and Nuclear Medicine, Erasmus Medisch Centrum, Rotterdam, The Netherlands
| | - S Modi
- Department of Radiology, University Hospital Southampton NHS, Southampton, UK
| | - N Montanari
- Department of Radiology, Ospedale Maggiore Di Bologna, Bologna, Italy
| | - J Navines
- Department of Surgery, University Hospital Germans Trias I Pujol, Badalona, Spain
| | - U P Neumann
- Department of Surgery, Maastricht University Medical Center, Maastricht, The Netherlands
- Department of General, Visceral and Transplant Surgery, University Hospital Aachen, Aachen, Germany
| | - P Peddu
- Department of Radiology, King's College Hospital NHS, London, UK
| | - J N Primrose
- Department of Surgery, University Hospital Southampton NHS, Southampton, UK
| | - X Qu
- Department of Radiology, Zhongshan Hospital, Fundan University, Shanghai, China
| | - D Raptis
- Department of Surgery, Royal Free Hospital NHS, London, UK
| | - F Ratti
- Department of Surgery, Ospedale San Raffaele, Milan, Italy
| | - F Ridouani
- Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, USA
| | - C Rogan
- Department of Radiology, Royal Prince Alfred Hospital, Camperdown, Australia
| | - U Ronellenfitsch
- Department of Surgery, University Hospital Halle (Saale), Halle, Germany
| | - S Ryan
- Department of Radiology, The Ottawa Hospital, Ottawa, Canada
| | - C Sallemi
- Department of Radiology, Fondazione Poliambulanza, Brescia, Italy
| | - J Sampere Moragues
- Department of Radiology, University Hospital Germans Trias I Pujol, Badalona, Spain
| | - P Sandström
- Department of Surgery, Biomedical and Clinical Sciences, Linköping University Hospital, Linköping, Sweden
| | - L Sarriá
- Department of Radiology, University Hospital Miguel Servet, Saragossa, Spain
| | - A Schnitzbauer
- Department of Surgery, University Hospital Frankfurt, Frankfurt, Germany
| | - M Serenari
- Department of Surgery, General Surgery and Transplant Unit, IRCCS Azienda Ospedaliero- Universitaria di Bologna, Sant'Orsola-Malpighi Hospital, Bologna, Italy
| | - A Serrablo
- Department of Surgery, University Hospital Miguel Servet, Saragossa, Spain
| | - M L J Smits
- Department of Radiology, University Medical Center Utrecht, Utrecht, The Netherlands
| | - E Sparrelid
- Department of Surgery, Karolinska University Hospital, Stockholm, Sweden
| | - E Spüntrup
- Department of Radiology, Klinikum Saarbrücken gGmbH, Saarbrücken, Germany
| | - G A Stavrou
- Department of Surgery, Klinikum Saarbrücken gGmbH, Saarbrücken, Germany
| | - R P Sutcliffe
- Department of Surgery, Queen Elizabeth Hospital Birmingham NHS, Birmingham, UK
| | - I Tancredi
- Department of Radiology, Hôpital Erasme, Brussels, Belgium
| | - J C Tasse
- Department of Radiology, Rush University Medical Center, Chicago, USA
| | - V Udupa
- Department of Surgery, Oxford University Hospital NHS, Oxford, UK
| | - D Valenti
- Department of Radiology, McGill University Health Centre, Montréal, Canada
| | - Y Fundora
- Department of Surgery, Hospital Clínic de Barcelona, Barcelona, Spain
| | - T J Vogl
- Department of Radiology, University Hosptital Frankfurt, Frankfurt, Germany
| | - X Wang
- Department of Surgery, Zhongshan Hospital, Fundan University, Shanghai, China
| | - S A White
- Department of Surgery, Newcastle Upon Tyne Hospitals NHS, Newcastle upon Tyne, UK
| | - W A Wohlgemuth
- Department of Radiology, University Hospital Halle (Saale), Halle, Germany
| | - D Yu
- Department of Radiology, Royal Free Hospital NHS, London, UK
| | - I A J Zijlstra
- Department of Radiology, Amsterdam University Medical Centers Location VU, Amsterdam, The Netherlands
| | - C A Binkert
- Department of Radiology, Cantonal Hospital Winterthur, Winterthur, Switzerland
| | - M H A Bemelmans
- Department of Surgery, Maastricht University Medical Center, Maastricht, The Netherlands
- Department of General, Visceral and Transplant Surgery, University Hospital Aachen, Aachen, Germany
| | - C van der Leij
- Deparment of Radiology and Nuclear Medicine, Maastricht University Medical Center, Maastricht, The Netherlands
| | - E Schadde
- Department of General and Visceral Surgery, Cantonal Hospital Winterthur, Winterthur, Switzerland
- Department of Surgery, Rush University Medical Center Chicago, Chicago, USA
| | - R M van Dam
- GROW School for Oncology and Developmental Biology, Maastricht University, Maastricht Universiteitssingel 40 room 5.452, 6229 ET, Maastricht, The Netherlands.
- Department of Surgery, Maastricht University Medical Center, Maastricht, The Netherlands.
- Department of General, Visceral and Transplant Surgery, University Hospital Aachen, Aachen, Germany.
| |
Collapse
|
7
|
Cristina Cardia M, Francesca Palmas M, Casula L, Pisanu A, Marceddu S, Valenti D, Sinico C, Pini E, Scerba MT, Tweedie D, Greig NH, Rosa Carta A, Lai F. Nanocrystals as an effective strategy to improve Pomalidomide bioavailability in rodent. Int J Pharm 2022; 625:122079. [PMID: 35932932 DOI: 10.1016/j.ijpharm.2022.122079] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/16/2022] [Revised: 06/14/2022] [Accepted: 08/01/2022] [Indexed: 10/16/2022]
Abstract
Pomalidomide (POM) is an FDA-approved immunomodulatory imide drug (IMiDs) an it is effectively used in the treatment of multiple myeloma. IMiDs are analogs of the drug thalidomide and they have been repurposed for the treatment of several diseases such as psoriatic arthritis and Kaposi Sarcoma. In recent years, IMiDs have been also evaluated as a new treatment for neurological disorders with an inflammatory and neuroinflammatory component. POM draws particular interest for its potent anti-TNF-α activity at significantly lower concentrations than the parent compound thalidomide. However, POM's low water solubility underpins its low gastrointestinal permeability resulting in irregular and poor absorption. The purpose of this work was to prepare a POM nanocrystal-based formulation that could efficiently improve POM's plasma and brain concentration after intraperitoneal injection. POM nanocrystals prepared as a nanosuspension by the media milling method showed a mean diameter of 219 nm and a polydispersity index of 0.21. POM's nanocrystal solubility value (22.97 µg/mL) in phosphate buffer was about 1.58 folds higher than the POM raw powder. Finally, in vivo studies conducted in adult Male Sprague-Dawley rats indicated that POM nanocrystal ensured higher and longer-lasting drug levels in plasma and brain when compared with POM coarse suspension.
Collapse
Affiliation(s)
- Maria Cristina Cardia
- Department of Life and Environmental Sciences, Unit of Drug Sciences, University of Cagliari, Cagliari, Italy
| | | | - Luca Casula
- Department of Life and Environmental Sciences, Unit of Drug Sciences, University of Cagliari, Cagliari, Italy
| | - Augusta Pisanu
- National Research Council, Institute of Neuroscience, Cagliari, Italy
| | - Salvatore Marceddu
- Institute of Sciences of Food Production (ISPA-CNR), Baldinca (Sassari), Italy
| | - Donatella Valenti
- Department of Life and Environmental Sciences, Unit of Drug Sciences, University of Cagliari, Cagliari, Italy
| | - Chiara Sinico
- Department of Life and Environmental Sciences, Unit of Drug Sciences, University of Cagliari, Cagliari, Italy
| | - Elena Pini
- Department of Pharmaceutical Sciences, Università degli Studi di Milano, Italy
| | - Michael T Scerba
- Drug Design & Development Section, Translational Gerontology Branch, Intramural Research Program, National Institute on Aging, National Institutes of Health, Baltimore, MD, United States
| | - David Tweedie
- Drug Design & Development Section, Translational Gerontology Branch, Intramural Research Program, National Institute on Aging, National Institutes of Health, Baltimore, MD, United States
| | - Nigel H Greig
- Drug Design & Development Section, Translational Gerontology Branch, Intramural Research Program, National Institute on Aging, National Institutes of Health, Baltimore, MD, United States
| | - Anna Rosa Carta
- Department of Biomedical Sciences, University of Cagliari, Cagliari, Italy.
| | - Francesco Lai
- Department of Life and Environmental Sciences, Unit of Drug Sciences, University of Cagliari, Cagliari, Italy.
| |
Collapse
|
8
|
Zoughlami A, Bessissow A, Valenti D, Nawawi A, Zogopoulos G, Chen Y. A204 SINGLE OPERATOR CHOLANGIOSCOPY GUIDED ELECTROHYDRAULIC LITHOTRIPSY THROUGH A UNIQUE PERCUTANEOUS ACCESS FOR SEVERE RECURRENT PYOGENIC CHOLANGITIS: A CASE REPORT. J Can Assoc Gastroenterol 2022. [DOI: 10.1093/jcag/gwab049.203] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
Single operator cholangioscopy guided electrohydraulic lithotripsy (SOC-EHL) is effective in difficult biliary stones. SOC is usually introduced in a transpapilliary fashion via a duodenoscope (peroral SOC). This approach is limited in intrahepatic ductal access, especially in presence of distal strictures.
Aims
To report a case of ductal clearance using a unique percutaneous access of SOC-EHL in a patient with extensive intrahepatic stones in addition to a distal stricture.
Methods
A retrospective case report
Results
An 80 year old male known for a distal cholangiocarcinoma post-Whipple surgery presented with recurrent cholangitis. Computed tomography scan revealed dilated intrahepatic bile ducts in segments V and VII and a dilated posterior right hepatic duct (PRHD) with associated cholelithiasis. Peroral SOC was first performed using a therapeutic gastroscope. The hepaticojejunostomy was patent and the cholangioscope was easily introduced into the bile duct. No stones or strictures were found on inspection of the intra- and extra-hepatic biliary system. Due to cholangitis recurrence a left-sided percutaneous drain was placed. However, cholangiogram showed a normal biliary sytem with no filling defects. A right-sided PTC was then performed for source control. Repeat right-sided cholangiogram finally identified an extremely dilated PRHD with extensive filling defects and a stricture in the distal PRHD. The abnormal biliary segments were missed on peroral SOC and left-sided cholangiogram due to the tight stricture.
Percutaneous SOC-EHL was then planned. The abnormal segment could not be reached using the right sided access. The left system did not allow for easy PRHD access due to the stricture and angulation. In order to gain entry to the abnormal biliary segment, the PRHD stricture was dilated to 6mm with balloon angioplasty. A 0.035” guidewire was inserted from the left access and advanced to the extrahepatic bile duct. This wire was captured using a snare introduced from the right percutaneous access and pulled through the right side. This allowed wire tension to be optimally applied from both percutaneous accesses. A cholangioscope was then introduced over the wire from the left access and advanced into the abnormal PRHD with optimal wire tension at both ends. A large stone burden was noted on SOC and ductal clearance with EHL was achieved after two EHL sessions (Fig. 1). Final cholangiogram showed complete ductal clearance and there was no recurrence of cholangitis at an 18 month follow-up.
Conclusions
SOC-EHL is an important therapeutic modality but may be of limited effectivess for extensive intrahepatic stones. Our case suggests the possibility of using a percutaneous approach for SOC-EHL in intrahepatic stones with concomitant distal stricture.
Figure 1: A) Cholangiogram showing extensive intrahepatic stone burden; B) SOC-EHL via a percutaneous access with EHL; C) final cholangiogram showing complete ductal clearance.
Funding Agencies
None
Collapse
Affiliation(s)
- A Zoughlami
- Division of Gastroenterology and Hepatology, McGill University Health Centre, Montreal, QC, Canada
| | - A Bessissow
- Division of Interventional Radiology, McGill University Health Centre, Montreal, QC, Canada
| | - D Valenti
- Division of Interventional Radiology, McGill University Health Centre, Montreal, QC, Canada
| | - A Nawawi
- Department of Surgery, McGill University Health Centre, Montreal, QC, Canada
| | - G Zogopoulos
- Department of Surgery, McGill University Health Centre, Montreal, QC, Canada
| | - Y Chen
- Division of Gastroenterology and Hepatology, McGill University Health Centre, Montreal, QC, Canada
| |
Collapse
|
9
|
Caddeo C, Lucchesi D, Fernàndez-Busquets X, Valenti D, Penno G, Fadda AM, Pucci L. Efficacy of a resveratrol nanoformulation based on a commercially available liposomal platform. Int J Pharm 2021; 608:121086. [PMID: 34530099 DOI: 10.1016/j.ijpharm.2021.121086] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/26/2021] [Revised: 09/06/2021] [Accepted: 09/10/2021] [Indexed: 12/18/2022]
Abstract
Scalability is one of the important factors slowing down or even impeding the clinical translation of nanoparticle-based systems. The latter need to be manufactured at a high level of quality, with batch-to-batch reproducibility, and need to be stable after the manufacturing process, during long-term storage and upon clinical administration. In this study, a vesicular formulation intended for cutaneous applications was developed by the easy reconstitution of a commercially available liposomal platform. Resveratrol, a naturally occurring compound with potent antioxidant activity, and Tween80, a hydrophilic non-ionic surfactant, were included in the formulation. The physico-chemical properties of the vesicles were assessed using light scattering and cryogenic transmission electron microscopy. Nanosized (around 80 nm) spherical and elongated, unilamellar vesicles were produced, with remarkable storage stability. The incorporation of resveratrol in the vesicular system did not alter its strong antioxidant activity, as demonstrated by antioxidant colorimetric assays (DPPH and FRAP). Furthermore, the resveratrol liposomes were cytocompatible with fibroblasts and capable of protecting skin cells from oxidative stress by reducing both endogenous and chemically induced reactive oxygen species more effectively than free resveratrol. Therefore, the proposed formulation, based on the use of a commercially available liposomal platform, represents an easy-to-prepare, reproducible, up-scaled and efficient means of delivering resveratrol and potentiating its biological activity in vitro.
Collapse
Affiliation(s)
- Carla Caddeo
- Dept. of Scienze della Vita e dell'Ambiente, Sezione di Scienze del Farmaco, University of Cagliari, Via Ospedale 72, 09124 Cagliari, Italy.
| | - Daniela Lucchesi
- Dept. of Clinical and Experimental Medicine, Section of Diabetes and Metabolic Diseases, University of Pisa, via Piero Trivella, 56124 Pisa, Italy
| | - Xavier Fernàndez-Busquets
- Nanomalaria Group, Institute for Bioengineering of Catalonia (IBEC), The Barcelona Institute of Science and Technology, Baldiri Reixac 10-12, Barcelona E08028, Spain; Barcelona Institute for Global Health (ISGlobal), Hospital Clínic-Universitat de Barcelona, Rosselló 149-153, Barcelona E08036, Spain
| | - Donatella Valenti
- Dept. of Scienze della Vita e dell'Ambiente, Sezione di Scienze del Farmaco, University of Cagliari, Via Ospedale 72, 09124 Cagliari, Italy
| | - Giuseppe Penno
- Dept. of Clinical and Experimental Medicine, Section of Diabetes and Metabolic Diseases, University of Pisa, via Piero Trivella, 56124 Pisa, Italy
| | - Anna Maria Fadda
- Dept. of Scienze della Vita e dell'Ambiente, Sezione di Scienze del Farmaco, University of Cagliari, Via Ospedale 72, 09124 Cagliari, Italy
| | - Laura Pucci
- Institute of Agricultural Biology and Biotechnology, CNR Pisa, Via Moruzzi 1, 56124 Pisa, Italy.
| |
Collapse
|
10
|
Dixon J, Mirtorabi N, Valenti D. Profunda femoris mycotic aneurysm as a complication of bacterial endocarditis: a case report and review of the literature. Ann R Coll Surg Engl 2021; 103:e259-e261. [PMID: 34464558 DOI: 10.1308/rcsann.2020.7117] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
Profunda femoris aneurysms account for only 0.5% of all peripheral artery aneurysms. This case documents a profunda femoris mycotic aneurysm (MA) in a 47-year-old woman, three years post-treatment of bacterial endocarditis. The patient underwent an open surgical excision of the aneurysm with antibiotic cover and made a successful recovery. A literature review was carried out to look at other MA cases to summarise the most common presentations, infective agents and management strategies.
Collapse
Affiliation(s)
- J Dixon
- Royal Berkshire Hospital, UK
| | | | | |
Collapse
|
11
|
Casula L, Lai F, Pini E, Valenti D, Sinico C, Cardia MC, Marceddu S, Ailuno G, Fadda AM. Pulmonary Delivery of Curcumin and Beclomethasone Dipropionate in a Multicomponent Nanosuspension for the Treatment of Bronchial Asthma. Pharmaceutics 2021; 13:pharmaceutics13081300. [PMID: 34452261 PMCID: PMC8401312 DOI: 10.3390/pharmaceutics13081300] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/21/2021] [Revised: 08/16/2021] [Accepted: 08/18/2021] [Indexed: 11/16/2022] Open
Abstract
Curcumin has shown a potential extraordinary activity as an add-on ingredient in asthma treatment, due to its immunomodulatory and anti-inflammatory mechanism of action. However, its low water solubility and bioavailability lead to a poor therapeutic effect, which can be overcome by its formulation as nanocrystals. The aim of this study was to prepare a multicomponent formulation for the delivery of curcumin (CUR) and beclomethasone dipropionate (BDP) into the lungs as water-based nanosuspensions (NS). Single component formulations (CUR-NS, BDP-NS) and a multicomponent formulation (CUR+BDP-NS) were prepared through a wet ball media milling technique, using P188 as a non-toxic stabilizer. Characterization was carried out in terms of size, size distribution, zeta potential, nanocrystals morphology, and solid-state properties. Moreover, the inhalation delivery efficiency was studied with Next Generation Impactor (NGI, Apparatus E Ph. Eu). CUR-NS was optimized and showed a long-term stability and improved nanocrystals apparent solubility. The three formulations exhibited a nanocrystal mean diameter in the range of 200-240 nm and a homogenous particle size distribution. Aggregation or sedimentation phenomena were not observed in the multicomponent formulation on 90 days storage at room temperature. Finally, the nebulization tests of the three samples showed optimal aerodynamic parameters and MMAD < 5 µm.
Collapse
Affiliation(s)
- Luca Casula
- Dipartimento di Scienze della Vita e dell’Ambiente, Sezione di Scienze del Farmaco, Università degli Studi di Cagliari, 09124 Cagliari, Italy; (L.C.); (F.L.); (D.V.); (C.S.); (M.C.C.)
| | - Francesco Lai
- Dipartimento di Scienze della Vita e dell’Ambiente, Sezione di Scienze del Farmaco, Università degli Studi di Cagliari, 09124 Cagliari, Italy; (L.C.); (F.L.); (D.V.); (C.S.); (M.C.C.)
| | - Elena Pini
- DISFARM, Sezione di Chimica Generale e Organica “A. Marchesini”, Università degli Studi di Milano, Via Venezian 21, 20133 Milano, Italy;
| | - Donatella Valenti
- Dipartimento di Scienze della Vita e dell’Ambiente, Sezione di Scienze del Farmaco, Università degli Studi di Cagliari, 09124 Cagliari, Italy; (L.C.); (F.L.); (D.V.); (C.S.); (M.C.C.)
| | - Chiara Sinico
- Dipartimento di Scienze della Vita e dell’Ambiente, Sezione di Scienze del Farmaco, Università degli Studi di Cagliari, 09124 Cagliari, Italy; (L.C.); (F.L.); (D.V.); (C.S.); (M.C.C.)
| | - Maria Cristina Cardia
- Dipartimento di Scienze della Vita e dell’Ambiente, Sezione di Scienze del Farmaco, Università degli Studi di Cagliari, 09124 Cagliari, Italy; (L.C.); (F.L.); (D.V.); (C.S.); (M.C.C.)
| | - Salvatore Marceddu
- Istituto di Scienze delle Produzioni Alimentari (ISPA)-CNR, Sez. di Sassari, 07040 Baldinca, Italy;
| | - Giorgia Ailuno
- Department of Pharmacy, University of Genova, 16147 Genova, Italy;
| | - Anna Maria Fadda
- Dipartimento di Scienze della Vita e dell’Ambiente, Sezione di Scienze del Farmaco, Università degli Studi di Cagliari, 09124 Cagliari, Italy; (L.C.); (F.L.); (D.V.); (C.S.); (M.C.C.)
- Correspondence: ; Tel.: +39-070-675-8565
| |
Collapse
|
12
|
Maggiolo F, Gianotti N, Comi L, Di Filippo E, Fumagalli L, Nozza S, Galli L, Valenti D, Rizzi M, Castagna A. Rilpivirine plus cobicistat-boosted darunavir as a two-drug switch regimen in HIV-infected, virologically suppressed subjects on steady standard three-drug therapy: a randomized, controlled, non-inferiority trial (PROBE 2). J Antimicrob Chemother 2021; 75:1332-1337. [PMID: 32129855 DOI: 10.1093/jac/dkaa018] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/14/2019] [Revised: 01/08/2020] [Accepted: 01/12/2020] [Indexed: 01/20/2023] Open
Abstract
BACKGROUND We explored the combination of rilpivirine plus cobicistat-boosted darunavir [a two-drug regimen (2DR)] when switching from standard triple combined ART. METHODS In this randomized, open-label, non-inferiority trial, participants had an HIV-RNA <50 copies/mL on a stable (>6 months) three-drug regimen. The primary endpoint was proportion with HIV-RNA <50 copies/mL at Week 24 (snapshot algorithm), with a -12% non-inferiority margin. ClinicalTrials.gov: NCT04064632. RESULTS One hundred and sixty patients were allocated (1:1) to 2DR or to continue current ART (CAR). At Week 24, 72 (90.0%) of participants with 2DR and 75 (93.8%) with CAR maintained HIV-RNA <50 copies/mL [difference -3.75% (95% CI = -11.63 to 5.63)], confirming non-inferiority. Non-inferiority was confirmed considering an HIV-RNA >50 copies/mL (0% for 2DR; 3.7% for CAR; 95% CI = -0.4 to 7.9). Four patients reported adverse events not leading to treatment discontinuation (one patient in the 2DR group and three patients in the CAR group); eight subjects discontinued therapy in the 2DR group and three in the CAR group. With 2DR, lipid serum concentrations increased, but differences were statistically significant only for tenofovir disoproxil fumarate-containing CAR and in 2DR patients receiving a pre-switch regimen including tenofovir disoproxil fumarate. Median bone stiffness decreased in the CAR group from 86.1 g/cm2 (IQR = 74-98) to 83.2 g/cm2 (IQR = 74-97) and increased in the 2DR group from 84.9 g/cm2 (IQR = 74-103) to 85.5 g/cm2 (IQR = 74-101). The reduction within the CAR group was significant (P = 0.043). CONCLUSIONS Once-daily rilpivirine plus cobicistat-boosted darunavir is an effective 2DR that combines a high virological efficacy with a potential to avoid major NRTI toxicities.
Collapse
Affiliation(s)
- F Maggiolo
- ASST Papa Giovanni XXIII, Bergamo, Italy
| | - N Gianotti
- San Raffaele Scientific Institute, Milan, Italy
| | - L Comi
- ASST Papa Giovanni XXIII, Bergamo, Italy
| | | | - L Fumagalli
- San Raffaele Scientific Institute, Milan, Italy
| | - S Nozza
- San Raffaele Scientific Institute, Milan, Italy
| | - L Galli
- San Raffaele Scientific Institute, Milan, Italy
| | | | - M Rizzi
- ASST Papa Giovanni XXIII, Bergamo, Italy
| | - A Castagna
- San Raffaele Scientific Institute, Milan, Italy.,Vita-Salute San Raffaele University, Milan, Italy
| |
Collapse
|
13
|
Sinico C, Maria Fadda A, Valenti D, Pireddu R, Corrias F, Schlich M, Pitzanti G, Lai F. Nanoliposomes@Transcutol for In Vitro Skin Delivery of 8-Methoxypsoralen. J Nanosci Nanotechnol 2021; 21:2901-2906. [PMID: 33653456 DOI: 10.1166/jnn.2021.19047] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/12/2023]
Abstract
8-methoxypsoralen is the most common drug in psoralen plus ultraviolet light irradiation therapy for the treatment of severe psoriasis. Despite of the efficacy, its classic oral administration leads to several serious adverse effects. However, the topical psoralen application produces a drug skin accumulation lower than that obtained by oral administration, due to the drug low skin permeability. In this paper, 8-methoxypsoralen loaded Penetration Enhancer-containing Vesicles were prepared using soy phosphatidylcholine and the penetration enhancer Transcutol® (5% or 10%) and characterized in terms of size, polydispersity index, zeta potential and encapsulation efficiency. No statistically significant differences in both size (~135 nm) and encapsulation efficiency (~65%) were found for different Transcutol® concentration. Transdermal delivery study assessed by Franz diffusion cells, showed that the 8-methoxypsoralen mainly accumulated into the stratum corneum. Moreover, after Penetration Enhancer-containing Vesicles application, the drug recovered in this layer is almost double of that delivered by conventional liposomes, while no significant difference was found from the different Transcutol® concentrations. Finally, biocompatibility checked by an MTT assay, demonstrated that the incubation of human keratinocytes for 24 h with 8-methoxypsoralen loaded Penetration Enhancer-containing Vesicles did not significantly reduce cell viability.
Collapse
Affiliation(s)
- Chiara Sinico
- Department of Life and Environmental Sciences, University of Cagliari, Cagliari 09124, Italy
| | - Anna Maria Fadda
- Department of Life and Environmental Sciences, University of Cagliari, Cagliari 09124, Italy
| | - Donatella Valenti
- Department of Life and Environmental Sciences, University of Cagliari, Cagliari 09124, Italy
| | - Rosa Pireddu
- Department of Life and Environmental Sciences, University of Cagliari, Cagliari 09124, Italy
| | - Francesco Corrias
- Department of Life and Environmental Sciences, University of Cagliari, Cagliari 09124, Italy
| | - Michele Schlich
- Department of Life and Environmental Sciences, University of Cagliari, Cagliari 09124, Italy
| | - Giulia Pitzanti
- Department of Life and Environmental Sciences, University of Cagliari, Cagliari 09124, Italy
| | - Francesco Lai
- Department of Life and Environmental Sciences, University of Cagliari, Cagliari 09124, Italy
| |
Collapse
|
14
|
Pireddu R, Sinico C, Ennas G, Valenti D, Marongiu F, Maria Fadda A, Schlich M, Lai F. Nanocrystals as Tool to Enhance Stigmasterol Oral Bioavailability. J Nanosci Nanotechnol 2021; 21:2946-2948. [PMID: 33653464 DOI: 10.1166/jnn.2021.19046] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/12/2023]
Abstract
Phytosterols are sterols naturally occurring in plant cells and well known for their cholesterollowering activity, as witnessed by the large number of food supplements based on these functional ingredients available on the market. However, the marked hydrophobic character of phytosterols makes their solubility in biological fluids extremely low, with disadvantageous consequences on the bioavailability and therapeutic efficacy. In this work, we explore the effect of particle size reduction on the water solubility of stigmasterol, one of the most abundant phytosterols, through the formulation of nanocystals. A robust, top-down production process was employed to prepare stigmasterol nanocrystals, subsequently characterized by thermal and spectroscopic techniques. When formulated as nanocrystals, the solubility of stigmasterol in water and in simulated gastro-intestinal fluids was boosted compared to the raw material. The increased solubility of stigmasterol nanocrystals makes such formulation a promising candidate for the development of medicinal/nutraceutical products with enhanced bioavailability.
Collapse
Affiliation(s)
- Rosa Pireddu
- Department of Life and Environmental Sciences, University of Cagliari, Via Ospedale 72, Cagliari, 09124, Italy
| | - Chiara Sinico
- Department of Life and Environmental Sciences, University of Cagliari, Via Ospedale 72, Cagliari, 09124, Italy
| | - Guido Ennas
- Department of Chemical and Geological Sciences, University of Cagliari, s.s. 554 Bivio Sestu, 09042 Monserrato, CA, Italy
| | - Donatella Valenti
- Department of Life and Environmental Sciences, University of Cagliari, Via Ospedale 72, Cagliari, 09124, Italy
| | - Francesca Marongiu
- Department of Life and Environmental Sciences, University of Cagliari, Via Ospedale 72, Cagliari, 09124, Italy
| | - Anna Maria Fadda
- Department of Life and Environmental Sciences, University of Cagliari, Via Ospedale 72, Cagliari, 09124, Italy
| | - Michele Schlich
- Department of Life and Environmental Sciences, University of Cagliari, Via Ospedale 72, Cagliari, 09124, Italy
| | - Francesco Lai
- Department of Life and Environmental Sciences, University of Cagliari, Via Ospedale 72, Cagliari, 09124, Italy
| |
Collapse
|
15
|
Shaghayegh Alavi S, Hadi Razavi S, Khodaiyan F, Cristina Cardia M, Lai F, Valenti D, Pini E, Rosa A, Nieddu M, Fadda AM. Proniosomal Formulation Encapsulating Pomegranate Peel Extract for Nutraceutical Applications. J Nanosci Nanotechnol 2021; 21:2907-2916. [PMID: 33653457 DOI: 10.1166/jnn.2021.19055] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/12/2023]
Abstract
In this study, pomegranate peel as a traditional natural remedy was extracted and encapsulated in proniosomal systems in order to improve its stability against harsh environmental conditions. Pomegranate peel was extracted by using sonication as a green extraction technology and the antioxidant activity of the obtained extract was evaluated to be 85.37% by 2,2-diphenyl-1-picrylhydrazyl (DPPH) radicals. Proniosomal powder was prepared based on the slurry method with a mixture of non-ionic surfactants namely span 60 and tween 20 in combination with cholesterol as a bilayer stabilizer. Proniosome-derived niosomes were achieved by hydration of the powder with water. The obtained vesicles were evaluated for their particle size, morphological observations, entrapment efficiency, cytotoxicity assay, DPPH antioxidant activity and, physical stability at 4 °C for 28 days. The results demonstrated that the proniosome-derived niosomes were of small size (198.16 nm for unloaded and 411.3 for extract loaded), quite homogeneous (PDI = 0.188 for unloaded and 0.216 for loaded) with highly negative charged spherical vesicles and showed appropriate physical stability during the time of storage. The encapsulation efficiency was 68.43±0.24% and the cytotoxicity assay proved that the formulations were not toxic against 3T3 fibroblast cells in the applied concentration.
Collapse
Affiliation(s)
- Seyedeh Shaghayegh Alavi
- Department of Food Science, Engineering and Technology, Faculty of Agricultural Engineering and Technology, University of Tehran, Karaj 3158777871, Iran
| | - Seyed Hadi Razavi
- Department of Food Science, Engineering and Technology, Faculty of Agricultural Engineering and Technology, University of Tehran, Karaj 3158777871, Iran
| | - Faramarz Khodaiyan
- Department of Food Science, Engineering and Technology, Faculty of Agricultural Engineering and Technology, University of Tehran, Karaj 3158777871, Iran
| | - Maria Cristina Cardia
- Department of Life and Environmental Sciences, Unit of Drug Sciences, University of Cagliari, Cagliari 09124, Italy
| | - Francesco Lai
- Department of Life and Environmental Sciences, Unit of Drug Sciences, University of Cagliari, Cagliari 09124, Italy
| | - Donatella Valenti
- Department of Life and Environmental Sciences, Unit of Drug Sciences, University of Cagliari, Cagliari 09124, Italy
| | - Elena Pini
- Department of Pharmaceutical Science-Sezione di Chimica Generale e Organica "A. Marchesini," Università degli Studi di Milano, Milan, 20133, Italy
| | - Antonella Rosa
- Department of Biomedical Science, University of Cagliari, 09042 Monserrato (CA), Italy
| | - Mariella Nieddu
- Department of Biomedical Science, University of Cagliari, 09042 Monserrato (CA), Italy
| | - Anna Maria Fadda
- Department of Life and Environmental Sciences, Unit of Drug Sciences, University of Cagliari, Cagliari 09124, Italy
| |
Collapse
|
16
|
Marino A, Bessissow A, Valenti D, Boucher L, Miller C, Forbes N, Chaudhury P, Martel M, Chen Y. A132 ENDOSCOPIC ULTRASOUND-GUIDED GASTROENTEROSTOMY USING A NOVEL DOUBLE BALLOON DEVICE IN THE MANAGEMENT OF MALIGNANT GASTRIC OUTLET OBSTRUCTION. J Can Assoc Gastroenterol 2021. [DOI: 10.1093/jcag/gwab002.130] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
EUS-gastroenterostomy (EUS-GE) is a novel modality in the management of malignant gastric outlet obstruction (MGOO). It is, however, technically challenging limiting its widespread application. To facilitate EUS-GE, a double balloon catheter has been developed in Japan. While this tool is not available outside of Asia, we have conceived a similar device using a widely available vascular balloon catheter. We aim to determine the clinical efficacy and safety of EUS-GE using this double balloon device (DBD).
Aims
We aim to determine the clinical efficacy and safety of EUS-GE using this double balloon device (DBD).
Methods
This is a single-centre, retrospective study of consecutive patients who underwent DBD assisted EUS-GE for MGOO from January 2019-June 2020 (IRB approved). The DBD consists of two 60 mm vascular balloons (Coda, Cook Medical, USA) fashioned together with the balloons 10 cm apart (Figure 1). It is inserted across the obstruction over a wire to the ligaments of Treitz. Both balloons are then inflated followed by saline and contrast infusion into the occluded small bowel segment to facilitate EUS-guided insertion of a 15 mm cautery assisted lumen apposing metal stent (AxiosTM, Boston Scientific Inc, USA). The primary endpoint is the rate of technical success defined as adequate deployment of the stent. Secondary endpoints include rate of clinical success and adverse events.
Results
A total of 11 patients were included in this study. 45% were female with a mean age of 64.9 ± 8.6 years old. The etiology of MGOO was 73% pancreatic cancer, 9% gastric cancer, 9% duodenal cancer, and 9% metastatic cervical cancer. Procedures were performed under general anesthesia and conscious sedation in 82% and 18%, of patients respectively. The mean procedure time was 64.8 ± 25.8 minutes. Technical and clinical success (intention to treat) was 91%. The only technical failure was due to poor patient tolerance of the procedure under conscious sedation. There was one adverse event (9%) due to stent migration rated as severe. Two patients (18%) required re-intervention for stent obstruction secondary to food impaction associated with non-compliance to a low-residue diet. Following re-enforced instructions, no further obstruction occurred.
All patients started a clear liquid diet within 1 day of the procedure with a mean time to a low residue diet of 3.25 days ± 2.5. The median length of hospital stay following the procedure was 5 days ± 13. The median follow-up time was 84 days (IQR 152).
Conclusions
DBD assisted EUS-GE is clinically effective and safe. This balloon device may greatly facilitate the technical aspect of EUS-GE while potential enhancing its safety and clinical use. Larger studies are needed to validate this approach to EUS-GE.
Funding Agencies
None
Collapse
Affiliation(s)
- A Marino
- McGill University, Hampstead, QC, Canada
| | - A Bessissow
- Divison of Gastroenterology and Hepatology, McGill University Health Centre, Outremont, QC, Canada
| | - D Valenti
- Divison of Gastroenterology and Hepatology, McGill University Health Centre, Outremont, QC, Canada
| | - L Boucher
- Divison of Gastroenterology and Hepatology, McGill University Health Centre, Outremont, QC, Canada
| | - C Miller
- Sir Mortimer B Davis Jewish General Hospital, Montreal, QC, Canada
| | - N Forbes
- University of Calgary, Calgary, AB, Canada
| | - P Chaudhury
- Divison of Gastroenterology and Hepatology, McGill University Health Centre, Outremont, QC, Canada
| | - M Martel
- Divison of Gastroenterology and Hepatology, McGill University Health Centre, Outremont, QC, Canada
| | - Y Chen
- Divison of Gastroenterology and Hepatology, McGill University Health Centre, Outremont, QC, Canada
| |
Collapse
|
17
|
Casula L, Sinico C, Valenti D, Pini E, Pireddu R, Schlich M, Lai F, Maria Fadda A. Delivery of beclomethasone dipropionate nanosuspensions with an electronic cigarette. Int J Pharm 2021; 596:120293. [PMID: 33497704 DOI: 10.1016/j.ijpharm.2021.120293] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/23/2020] [Revised: 01/16/2021] [Accepted: 01/17/2021] [Indexed: 01/14/2023]
Abstract
The aim of this work was to ascertain the ability of electronic nicotine delivery systems (ENDS) to deliver drug nanocrystals through the produced aerosol. A nanocrystal nanosuspension of beclomethasone dipropionate, a synthetic chlorinated corticosteroid diester commonly used by inhalation in the treatment of asthma and chronic obstructive pulmonary disease, was prepared with a wet media milling technique using Poloxamer 188 as stabilizer. The obtained nanosuspension was thoroughly characterized by different techniques: transmission electron microscopy, photon correlation spectroscopy, X-ray powder diffractometry and Fourier transform infrared spectroscopy. The nanosuspension was then loaded in the cartomizer of the electronic cigarette and the produced aerosol was collected and analysed, confirming the presence of drug nanocrystals. The results of this study suggested the possible alternative use of ENDS as medical device for the delivery of poorly soluble drugs.
Collapse
Affiliation(s)
- Luca Casula
- Dipartimento di Scienze della Vita e dell'Ambiente, Sezione di Scienze del Farmaco, CNBS, Università degli Studi di Cagliari, Cagliari 09124, Italy
| | - Chiara Sinico
- Dipartimento di Scienze della Vita e dell'Ambiente, Sezione di Scienze del Farmaco, CNBS, Università degli Studi di Cagliari, Cagliari 09124, Italy
| | - Donatella Valenti
- Dipartimento di Scienze della Vita e dell'Ambiente, Sezione di Scienze del Farmaco, CNBS, Università degli Studi di Cagliari, Cagliari 09124, Italy
| | - Elena Pini
- DISFARM, Sezione di Chimica Generale e Organica "A. Marchesini", Università degli Studi di Milano, Via Venezian 21, Milano 20133, Italy
| | - Rosa Pireddu
- Dipartimento di Scienze della Vita e dell'Ambiente, Sezione di Scienze del Farmaco, CNBS, Università degli Studi di Cagliari, Cagliari 09124, Italy
| | - Michele Schlich
- Dipartimento di Scienze della Vita e dell'Ambiente, Sezione di Scienze del Farmaco, CNBS, Università degli Studi di Cagliari, Cagliari 09124, Italy; Laboratory of Nanotechnology for Precision Medicine, Istituto Italiano di Tecnologia, Genova 16163, Italy
| | - Francesco Lai
- Dipartimento di Scienze della Vita e dell'Ambiente, Sezione di Scienze del Farmaco, CNBS, Università degli Studi di Cagliari, Cagliari 09124, Italy.
| | - Anna Maria Fadda
- Dipartimento di Scienze della Vita e dell'Ambiente, Sezione di Scienze del Farmaco, CNBS, Università degli Studi di Cagliari, Cagliari 09124, Italy
| |
Collapse
|
18
|
Caddeo C, Gabriele M, Nácher A, Fernàndez-Busquets X, Valenti D, Maria Fadda A, Pucci L, Manconi M. Resveratrol and artemisinin eudragit-coated liposomes: A strategy to tackle intestinal tumors. Int J Pharm 2020; 592:120083. [PMID: 33197563 DOI: 10.1016/j.ijpharm.2020.120083] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/15/2020] [Revised: 11/06/2020] [Accepted: 11/08/2020] [Indexed: 10/23/2022]
Abstract
Resveratrol and artemisinin, two naturally occurring compounds with a wide range of biological activities, have been reported to exert antitumor effects against several types of cancer. In this work, Eudragit-coated liposomes were developed to safely transport resveratrol and artemisinin through the gastrointestinal tract and target the intestine. The physico-chemical properties of the Eudragit-coated liposomes were assessed by light scattering and cryogenic transmission electron microscopy. Nanosized (around 100 nm), spherical or elongated, unilamellar vesicles were produced. The protective effect of the Eudragit coating was confirmed by assessing the physical stability of the vesicles in fluids mimicking the gastrointestinal environment. Furthermore, the vesicles were found to exert a pro-oxidant activity in intestinal adenocarcinoma cells, which resulted in a marked mortality due to the generation of reactive oxygen species (ROS). A time- and dose-dependent cell growth inhibitory effect was detected, with elevated ROS levels when resveratrol and artemisinin were combined. Therefore, the proposed formulations may represent a valuable means to counteract intestinal tumor growth.
Collapse
Affiliation(s)
- Carla Caddeo
- Dept. of Scienze della Vita e dell'Ambiente, Sezione di Scienze del Farmaco, University of Cagliari, Via Ospedale 72, 09124 Cagliari, Italy.
| | - Morena Gabriele
- Institute of Agricultural Biology and Biotechnology, CNR Pisa, Via Moruzzi 1, 56124 Pisa, Italy
| | - Amparo Nácher
- Dept. of Pharmacy and Pharmaceutical Technology, Faculty of Pharmacy, University of Valencia, Vicente Andrés Estellés s/n, 46100 Valencia, Spain; Instituto Interuniversitario de Investigación de Reconocimiento Molecular y Desarrollo Tecnológico (IDM), Universitat Politècnica de València, Universitat de València, Valencia, Spain
| | - Xavier Fernàndez-Busquets
- Nanomalaria Group, Institute for Bioengineering of Catalonia (IBEC), The Barcelona Institute of Science and Technology, Baldiri Reixac 10-12, Barcelona E08028, Spain; Barcelona Institute for Global Health (ISGlobal), Hospital Clínic-Universitat de Barcelona, Rosselló 149-153, Barcelona E08036, Spain
| | - Donatella Valenti
- Dept. of Scienze della Vita e dell'Ambiente, Sezione di Scienze del Farmaco, University of Cagliari, Via Ospedale 72, 09124 Cagliari, Italy
| | - Anna Maria Fadda
- Dept. of Scienze della Vita e dell'Ambiente, Sezione di Scienze del Farmaco, University of Cagliari, Via Ospedale 72, 09124 Cagliari, Italy
| | - Laura Pucci
- Institute of Agricultural Biology and Biotechnology, CNR Pisa, Via Moruzzi 1, 56124 Pisa, Italy.
| | - Maria Manconi
- Dept. of Scienze della Vita e dell'Ambiente, Sezione di Scienze del Farmaco, University of Cagliari, Via Ospedale 72, 09124 Cagliari, Italy
| |
Collapse
|
19
|
Liu DM, Hadjivassiliou A, Valenti D, Ho SG, Klass D, Chung JB, Kim PT, Boucher LM. Optimized nerve block techniques while performing percutaneous hepatic ablation: Literature review and practical use. J Interv Med 2020; 3:161-166. [PMID: 34557322 PMCID: PMC7420394 DOI: 10.1016/j.jimed.2020.06.002] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/25/2020] [Accepted: 06/19/2020] [Indexed: 01/11/2023] Open
Abstract
Percutaneous image guided thermal ablation has become a cornerstone of therapy for patients with oligometastatic disease and primary liver malignancies. Evolving from percutaneous ethanol injection (PEI), thermal ablation utilizing radiofrequency ablation (RFA) and microwave ablation (MWA) have become the standard approach in the treatment of isolated lesions that fit within the size criteria for curative intent therapy (typically 3-4cm). With the evolution of more intense thermal ablation, such as MWA, the dramatic increase in both the size of ablation zone and intensity of heat generation have extended the limits of this technique. As a result of these innovations, intra-procedural and post-procedural pain have also significantly increased, requiring either higher levels of intravenous sedation or, in some institutions, general anesthesia. In addition to the increase in therapeutic intensity, the use of intravenous sedation during aggressive ablation procedures carries the risk of over-sedation when the noxious insult (i.e. the ablation) is removed, adding further difficulty to post-procedural recovery and management. Furthermore, high subdiaphragmatic lesions become challenging in this setting due to issues relating to sedation and compliance with breath hold/breathing instructions. Although general anesthesia may mitigate these complications, the added resources associated with providing general anesthesia during ablation is not cost effective and may result in substantial delays in treatment. The reduction of Aerosol Generating Medical Procedures (AGMP), such as intubation due to the COVID-19 Pandemic, must also be taken into consideration. Due to the potential increased risk of infection transmission, alternatives to general anesthesia should be considered when safe and possible. Upper abdominal regional nerve block techniques have been used to manage pain related to trauma, surgery, and cancer; however, blocks of this nature are not well described in the interventional radiology literature. The McGill University group has developed experience in using such blocks as splanchnic, celiac and hepatic hilar nerve blocks to provide peri-procedural pain control [1]. Since incorporating these techniques (along with hydrodissection with tumescent anesthesia), we have also observed in our high volume ablation center a dramatic decrease in the amount of sedatives administered during the procedure, a decrease in patient discomfort during localization and ablation, as well as decreased pain post-procedure. Faster time to discharge and overall reduction in room procedural time serve as added benefits. The purpose of this publication is to outline and illustrate the practical application and use of nerve block/regional anesthesia techniques with respect to percutaneous hepatic thermal ablation.
Collapse
Affiliation(s)
- D M Liu
- Associate Professor, Faculty of Medicine, University of British Columbia, Canada.,Voluntary Professor, Miller School of Medicine, University of Miami, USA.,Department of Radiology - Division of Interventional Radiology, Vancouver General Hospital, Canada.,Associate Professor, Faculty of Applied Science, University of British Columbia, Canada
| | - A Hadjivassiliou
- Department of Radiology - Division of Interventional Radiology, Vancouver General Hospital, Canada
| | - D Valenti
- Assistant Professor, Faculty of Medicine, McGill University, Department of Radiology, Division of Interventional Radiology, McGill University Health Centre, Montreal, Canada
| | - S G Ho
- Department of Radiology - Division of Interventional Radiology, Vancouver General Hospital, Canada.,Clinical Professor, Faculty of Medicine, University of British Columbia, Canada
| | - D Klass
- Department of Radiology - Division of Interventional Radiology, Vancouver General Hospital, Canada.,Clinical Associate Professor, Faculty of Medicine, University of British Columbia, Canada
| | - J B Chung
- Department of Radiology, Vancouver General Hospital, Canada.,Associate Professor, Faculty of Applied Science, University of British Columbia, Canada
| | - P T Kim
- Department of Surgery Division of Hepatopancraticobiliary Surgery/Liver Transplantation, Vancouver General Hospital, Vancouver, Canada.,Clinical Associate Professor, Faculty of Medicine, University of British Columbia, Canada
| | - L M Boucher
- Assistant Professor, Faculty of Medicine, McGill University, Department of Radiology, Division of Interventional Radiology, McGill University Health Centre, Montreal, Canada
| |
Collapse
|
20
|
Schlich M, Lai F, Pireddu R, Pini E, Ailuno G, Fadda AM, Valenti D, Sinico C. Resveratrol proniosomes as a convenient nanoingredient for functional food. Food Chem 2019; 310:125950. [PMID: 31830712 DOI: 10.1016/j.foodchem.2019.125950] [Citation(s) in RCA: 22] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/30/2019] [Revised: 11/11/2019] [Accepted: 11/23/2019] [Indexed: 12/18/2022]
Abstract
Proniosomes are free-flowing powders composed of water-soluble carriers blended with surfactants, which form niosomes upon hydration. In this work, proniosomal formulations containing the natural antioxidant resveratrol (RSV) were prepared and fully characterized. A pre-formulation study on RSV-loaded niosomes was carried out to determine the most promising ratio between the two surfactants, Tween 20 and Span 60, in terms of entrapment efficiency and antioxidant activity. The optimized formulae were subsequently adapted to be prepared as proniosomes by the slurry method, including lactose or maltodextrin as carriers. The impact of surfactants and carriers properties on size, entrapment efficiency and release kinetics of proniosomes were evaluated. In vitro release of RSV in simulated gastric and intestinal media was determined, as well as the vesicular stability. Moreover, the biocompatibility of the formulations was determined on intestinal cells in vitro. Overall, the developed proniosomes provide promising nanoingredient for functional food, improving resveratrol stability and bioavailability.
Collapse
Affiliation(s)
- M Schlich
- Dipartimento di Scienze della Vita e dell'Ambiente, Sezione di Scienze del Farmaco, University of Cagliari, CNBS, Via Ospedale 72, 09124 Cagliari, Italy
| | - F Lai
- Dipartimento di Scienze della Vita e dell'Ambiente, Sezione di Scienze del Farmaco, University of Cagliari, CNBS, Via Ospedale 72, 09124 Cagliari, Italy.
| | - R Pireddu
- Dipartimento di Scienze della Vita e dell'Ambiente, Sezione di Scienze del Farmaco, University of Cagliari, CNBS, Via Ospedale 72, 09124 Cagliari, Italy
| | - E Pini
- DISMAB-Sezione di Chimica Organica ''A.Marchesini'', Università degli Studi di Milano, Milano, Italy
| | - Giorgia Ailuno
- Dipartimento di Farmacia (DIFAR), University of Genova, Genova 16148, Italy
| | - A M Fadda
- Dipartimento di Scienze della Vita e dell'Ambiente, Sezione di Scienze del Farmaco, University of Cagliari, CNBS, Via Ospedale 72, 09124 Cagliari, Italy
| | - D Valenti
- Dipartimento di Scienze della Vita e dell'Ambiente, Sezione di Scienze del Farmaco, University of Cagliari, CNBS, Via Ospedale 72, 09124 Cagliari, Italy
| | - C Sinico
- Dipartimento di Scienze della Vita e dell'Ambiente, Sezione di Scienze del Farmaco, University of Cagliari, CNBS, Via Ospedale 72, 09124 Cagliari, Italy
| |
Collapse
|
21
|
Manca ML, Usach I, Peris JE, Ibba A, Orrù G, Valenti D, Escribano-Ferrer E, Gomez-Fernandez JC, Aranda FJ, Fadda AM, Manconi M. Optimization of Innovative Three-Dimensionally-Structured Hybrid Vesicles to Improve the Cutaneous Delivery of Clotrimazole for the Treatment of Topical Candidiasis. Pharmaceutics 2019; 11:pharmaceutics11060263. [PMID: 31174342 PMCID: PMC6630241 DOI: 10.3390/pharmaceutics11060263] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/07/2019] [Revised: 06/01/2019] [Accepted: 06/04/2019] [Indexed: 12/21/2022] Open
Abstract
New three-dimensionally-structured hybrid phospholipid vesicles, able to load clotrimazole in a high amount (10 mg/mL), were obtained for the first time in this work by significantly reducing the amount of water (≤10%), which was replaced with a mixture of glycerol and ethanol (≈90%). A pre-formulation study was carried out to evaluate the effect of both the composition of the hydrating medium and the concentration of the phospholipid on the physico-chemical properties of hybrid vesicles. Four different three-dimensionally-structured hybrid vesicles were selected as ideal systems for the topical application of clotrimazole. An extensive physico-chemical characterization performed using transmission electron microscopy (TEM), cryogenic transmission electron microscopy (cryo-TEM), 31P-NMR, and small-angle X-ray scattering (SAXS) displayed the formation of small, multi-, and unilamellar vesicles very close to each other, and was capable of forming a three-dimensional network, which stabilized the dispersion. Additionally, the dilution of the dispersion with water reduced the interactions between vesicles, leading to the formation of single unilamellar vesicles. The evaluation of the in vitro percutaneous delivery of clotrimazole showed an improved drug deposition in the skin strata provided by the three-dimensionally-structured vesicles with respect to the commercial cream (Canesten®) used as a reference. Hybrid vesicles were highly biocompatible and showed a significant antifungal activity in vitro, greater than the commercial cream Canesten®. The antimycotic efficacy of formulations was confirmed by the reduced proliferation of the yeast cells at the site of infection in vivo. In light of these results, clotrimazole-loaded, three-dimensionally-structured hybrid vesicles appear to be one of the most innovative and promising formulations for the treatment of candidiasis infections.
Collapse
Affiliation(s)
- Maria Letizia Manca
- Department Scienze della Vita e dell'Ambiente, University of Cagliari, Via Ospedale 72, 09124 Cagliari, Italy.
| | - Iris Usach
- Department of Pharmacy and Pharmaceutical Technology and Parasitology, University of Valencia, Burjassot, 46100 Valencia, Spain.
| | - José Esteban Peris
- Department of Pharmacy and Pharmaceutical Technology and Parasitology, University of Valencia, Burjassot, 46100 Valencia, Spain.
| | - Antonella Ibba
- Department of Surgical Science, University of Cagliari, Molecular Biology Service Lab (MBS), Via Ospedale 40, 09124 Cagliari, Italy.
| | - Germano Orrù
- Department of Surgical Science, University of Cagliari, Molecular Biology Service Lab (MBS), Via Ospedale 40, 09124 Cagliari, Italy.
| | - Donatella Valenti
- Department Scienze della Vita e dell'Ambiente, University of Cagliari, Via Ospedale 72, 09124 Cagliari, Italy.
| | - Elvira Escribano-Ferrer
- Biopharmaceutics and Pharmacokinetics Unit, Institute for Nanoscience and Nanotechnology, University of Barcelona, 08028 Barcelona, Spain.
| | - Juan Carmelo Gomez-Fernandez
- Department of Biochemistry and Molecular Biology A, Regional Campus of International Excellence Campus Mare Nostrum, University of Murcia, 30080 Murcia, Spain.
| | - Francisco José Aranda
- Department of Biochemistry and Molecular Biology A, Regional Campus of International Excellence Campus Mare Nostrum, University of Murcia, 30080 Murcia, Spain.
| | - Anna Maria Fadda
- Department Scienze della Vita e dell'Ambiente, University of Cagliari, Via Ospedale 72, 09124 Cagliari, Italy.
| | - Maria Manconi
- Department Scienze della Vita e dell'Ambiente, University of Cagliari, Via Ospedale 72, 09124 Cagliari, Italy.
| |
Collapse
|
22
|
Caddeo C, Gabriele M, Fernàndez-Busquets X, Valenti D, Fadda AM, Pucci L, Manconi M. Antioxidant activity of quercetin in Eudragit-coated liposomes for intestinal delivery. Int J Pharm 2019; 565:64-69. [DOI: 10.1016/j.ijpharm.2019.05.007] [Citation(s) in RCA: 54] [Impact Index Per Article: 10.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/12/2019] [Revised: 05/03/2019] [Accepted: 05/04/2019] [Indexed: 02/07/2023]
|
23
|
Amore E, Manca ML, Ferraro M, Valenti D, La Parola V, Di Vincenzo S, Gjomarkaj M, Giammona G, Bondì ML, Pace E. Salmeterol Xinafoate (SX) loaded into mucoadhesive solid lipid microparticles for COPD treatment. Int J Pharm 2019; 562:351-358. [PMID: 30935915 DOI: 10.1016/j.ijpharm.2019.03.059] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/07/2018] [Revised: 03/25/2019] [Accepted: 03/27/2019] [Indexed: 01/12/2023]
Abstract
Chronic obstructive pulmonary disease (COPD) is one of the main health problems worldwide. It is characterised by chronic inflammation in the lungs that leads to progressive, chronic, largely irreversible airflow obstruction. The use of long-acting β agonists remain today the frontline treatment for COPD with the aim of minimizing side effects and enhancing therapeutic usefulness. To this purpose, in this paper, mucoadhesive solid lipid microparticles (SLMs) containing a long-acting β-2 agonist, Salmeterol Xinafoate (SX) were prepared, characterised (size, z-potential, aerodynamic diameter, turbidimetric evaluations, drug loading and entrapping efficiency) and tested in a model of bronchial epithelial cells. It was demonstrated that the incorporation of SX into SLMs led to the production of particles suitable for inhalation and more efficient than the free molecule at increasing the cAMP expression in bronchial epithelial cells. In conclusion, the prepared systems, due to their aerodynamic behaviour and mucoadhesive properties, could improve the retention time of SX in the lung epithelium and its therapeutic effect, thus representing a good strategy for the treatment of COPD patients.
Collapse
Affiliation(s)
- Erika Amore
- Dipartimento di Scienze e Tecnologie Biologiche, Chimiche e Farmaceutiche (STEBICEF), Università degli Studi di Palermo, Via Archirafi 32, 90123 Palermo, Italy; Istituto per lo Studio dei Materiali Nanostrutturati (ISMN), U.O.S. Palermo, CNR, Via Ugo La Malfa, 153, 90146 Palermo, Italy
| | - Maria Letizia Manca
- Dipartimento Scienze della Vita e dell'Ambiente, Sezione Scienze del Farmaco, Università degli Studi di Cagliari, Via Ospedale 72, 09124 Cagliari, Italy
| | - Maria Ferraro
- Istituto di Biomedicina e Immunologia Molecolare (IBIM), CNR, Via Ugo La Malfa, 153, 90146 Palermo, Italy
| | - Donatella Valenti
- Dipartimento Scienze della Vita e dell'Ambiente, Sezione Scienze del Farmaco, Università degli Studi di Cagliari, Via Ospedale 72, 09124 Cagliari, Italy
| | - Valeria La Parola
- Istituto per lo Studio dei Materiali Nanostrutturati (ISMN), U.O.S. Palermo, CNR, Via Ugo La Malfa, 153, 90146 Palermo, Italy
| | - Serena Di Vincenzo
- Istituto di Biomedicina e Immunologia Molecolare (IBIM), CNR, Via Ugo La Malfa, 153, 90146 Palermo, Italy
| | - Mark Gjomarkaj
- Istituto di Biomedicina e Immunologia Molecolare (IBIM), CNR, Via Ugo La Malfa, 153, 90146 Palermo, Italy
| | - Gaetano Giammona
- Dipartimento di Scienze e Tecnologie Biologiche, Chimiche e Farmaceutiche (STEBICEF), Università degli Studi di Palermo, Via Archirafi 32, 90123 Palermo, Italy
| | - Maria Luisa Bondì
- Istituto per lo Studio dei Materiali Nanostrutturati (ISMN), U.O.S. Palermo, CNR, Via Ugo La Malfa, 153, 90146 Palermo, Italy
| | - Elisabetta Pace
- Istituto di Biomedicina e Immunologia Molecolare (IBIM), CNR, Via Ugo La Malfa, 153, 90146 Palermo, Italy.
| |
Collapse
|
24
|
Masckauchan M, Wong P, Valenti D. A200 UNUSUAL PERIANAL MASS IN A CIRRHOTIC PATIENT: A CASE REPORT. J Can Assoc Gastroenterol 2019. [DOI: 10.1093/jcag/gwz006.199] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
- M Masckauchan
- McGill University Health Centre, Montreal, QC, Canada
| | - P Wong
- McGill University Health Centre, Montreal, QC, Canada
| | - D Valenti
- McGill University Health Centre, Montreal, QC, Canada
| |
Collapse
|
25
|
Galeoto G, Sansoni J, Valenti D, Mollica R, Valente D, Parente M, Servadio A. The effect of physiotherapy on fatigue and physical functioning in chronic fatigue syndrome patients: A systematic review. Clin Ter 2018; 169:e184-e188. [PMID: 30151552 DOI: 10.7417/t.2018.2076] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
OBJECTIVE The objectives of this work were to fill the gap in the scientific literature and to evaluate the results of physical therapy treatments in individuals affected by chronic fatigue syndrome, considering only studies that employed a randomized controlled trial. METHODS A systematic review was carried out according to PRISMA guidelines. Three bibliographic databases were searched: MEDLINE, Cochrane Library, and PEDro. The minimum prerequisites for papers to be included in the systematic review were that they had to (a) employ a randomized controlled trial; (b) be published in English; and (c) be published during the last ten years (2007-2017). The studies were evaluated according to Jadad score. RESULTS Four studies were included. This systematic review suggests that a treatment that is more effective than all the others cannot be defined. This conclusion is related to the low number of investigated studies; therefore, the collected results cannot be generalized. CONCLUSION Chronic fatigue syndrome is not yet a well-understood pathology, and the physical mechanisms that influence the outcomes still need more study. Rehabilitation programs that promote physiotherapy techniques such as exercise, mobilization, and body awareness (e.g., MRT and GET) are the most effective in reducing medium and long-term fatigue severity in CFS patients.
Collapse
Affiliation(s)
- G Galeoto
- Department of Public Health, Sapienza University of Rome
| | - J Sansoni
- Department of Public Health, Sapienza University of Rome
| | - D Valenti
- Neuropsychiatric and rehabilitation nursing sciences, "Tor Vergata" II University of Rome
| | - R Mollica
- Department of Anatomical, Histological, Forensic and Orthopedic Sciences, "Sapienza" University of Rome
| | - D Valente
- Department of Paediatrics and Child Neuropsychiatry, "Sapienza" University of Rome
| | | | - A Servadio
- Department of Health Professions, Policlinico "Tor Vergata" of Rome, Italy
| |
Collapse
|
26
|
Valenti D. MARIJUANA: IMPAIRMENT TO THE VISUAL SENSORY SYSTEM. Innov Aging 2018. [DOI: 10.1093/geroni/igy031.3587] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
27
|
Hashim AA, Chen Y, Valenti D, Waschke K, Parent J, Metrakos P, white S, Barkun AN, Bessissow A. A267 EUS-GUIDED HEPATOGASTROSTOMY POST PERCUTANEOUS BILIARY DRAINAGE IN COLLABORATION WITH INTERVENTIONAL RADIOLOGY. J Can Assoc Gastroenterol 2018. [DOI: 10.1093/jcag/gwy009.267] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
- A A Hashim
- Division of Gastroenterology, McGill University Health Center, Montreal, QC, Canada
| | - Y Chen
- Division of Gastroenterology, McGill University Health Center, Montreal, QC, Canada
| | - D Valenti
- Division of Interventional Radiology, McGill University Health Center, Montreal, QC, Canada
| | - K Waschke
- Division of Gastroenterology, McGill University Health Center, Montreal, QC, Canada
| | - J Parent
- Division of Gastroenterology, McGill University Health Center, Montreal, QC, Canada
| | - P Metrakos
- Department of Surgery and Pathology, McGill University Health Center, Montreal, QC, Canada
| | - s white
- Royal Victoria Hospital, Montreal, QC, Canada
| | - A N Barkun
- Gastroenterology, McGill University, The Montreal General Hospital, GI Division, Montreal, QC, Canada
| | - A Bessissow
- Division of Interventional Radiology, McGill University Health Center, Montreal, QC, Canada
| |
Collapse
|
28
|
Hashim AA, Bessissow A, Valenti D, Waschke K, Parent J, Barkun AN, Barkun J, white S, Chen Y. A332 FIRST REPORTED EUS-GUIDED DOUBLE BYPASS PERFORMED IN COLLABORATION WITH INTERVENTIONAL RADIOLOGY. J Can Assoc Gastroenterol 2018. [DOI: 10.1093/jcag/gwy009.332] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
- A A Hashim
- Division of Gastroenterology, McGill University Health Center, Montreal, QC, Canada
| | - A Bessissow
- Division of Interventional Radiology, McGill University Health Center, Montreal, QC, Canada
| | - D Valenti
- Division of Interventional Radiology, McGill University Health Center, Montreal, QC, Canada
| | - K Waschke
- Division of Gastroenterology, McGill University Health Center, Montreal, QC, Canada
| | - J Parent
- Division of Gastroenterology, McGill University Health Center, Montreal, QC, Canada
| | - A N Barkun
- Gastroenterology, McGill University, The Montreal General Hospital, GI Division, Montreal, QC, Canada
| | - J Barkun
- Department of Surgery, McGill University Health Center, Montreal, QC, Canada
| | - s white
- Royal Victoria Hospital, Montreal, QC, Canada
| | - Y Chen
- Division of Gastroenterology, McGill University Health Center, Montreal, QC, Canada
| |
Collapse
|
29
|
Pireddu R, Pibiri M, Valenti D, Sinico C, Fadda AM, Simbula G, Lai F. A novel lactoferrin-modified stealth liposome for hepatoma-delivery of triiodothyronine. Int J Pharm 2018; 537:257-267. [PMID: 29294323 DOI: 10.1016/j.ijpharm.2017.12.048] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/19/2017] [Revised: 12/29/2017] [Accepted: 12/30/2017] [Indexed: 01/10/2023]
Abstract
Triiodothyronine (T3), a thyroid hormone synthesized and secreted by the thyroid gland, plays an essential role in morphogenesis and differentiation through interaction with its nuclear receptors (TRs). However, there are increasing evidences for its role in hepatocellular carcinoma (HCC) suppression. The aim of this work was to develop an effective hepatocellular carcinoma targeting drug delivery system to improve T3 delivery to hepatic cancer cells as well as to reduce toxic side effects. Three different liposomal systems, such as unmodified, Stealth (PEGylated) and Lactoferrin (Lf)-modified-Stealth liposomes were successfully prepared by the film hydration method, and fully characterized. Liposome cell interactions and cellular uptake were evaluated in three different HCC target cells (FaO, HepG2 and SKHep) by confocal microscopy. Finally, in vitro cytotoxicity studies were carried out by using MTT assay to evaluate toxicity of the liposome delivery system and to test the effect of T3 when incorporated into liposomes. Internalization studies, performed using Lf-modified-liposomes labeled with the lipophilic marker Rho-PE and loaded with the hydrophilic probe CF, clearly demonstrated the effective internalization of both hydrophilic and lipophilic markers. Lf-liposomes might markedly enhance the specific cell binding and cellular uptake in hepatoma cells due to the mediating of Lf that could bind with high affinity to multiple receptors on cell surface, such as ASGP-R. Results obtained from this study highlight that the Lf- modified-liposomal delivery system may ensure a specific and sustained T3 delivery, thus, allowing reduced therapeutic doses and deleterious side effects of T3.
Collapse
Affiliation(s)
- Rosa Pireddu
- Università degli Studi di Cagliari, Dept. Scienze della Vita e dell'Ambiente, University of Cagliari, via Ospedale 72, 09124, Cagliari, Italy
| | - Monica Pibiri
- Università degli Studi di Cagliari, Dept. of Biomedical Sciences, University of Cagliari, via Porcell 4, Cagliari, 09124, Italy
| | - Donatella Valenti
- Università degli Studi di Cagliari, Dept. Scienze della Vita e dell'Ambiente, University of Cagliari, via Ospedale 72, 09124, Cagliari, Italy
| | - Chiara Sinico
- Università degli Studi di Cagliari, Dept. Scienze della Vita e dell'Ambiente, University of Cagliari, via Ospedale 72, 09124, Cagliari, Italy
| | - Anna Maria Fadda
- Università degli Studi di Cagliari, Dept. Scienze della Vita e dell'Ambiente, University of Cagliari, via Ospedale 72, 09124, Cagliari, Italy
| | - Gabriella Simbula
- Università degli Studi di Cagliari, Dept. of Biomedical Sciences, University of Cagliari, via Porcell 4, Cagliari, 09124, Italy
| | - Francesco Lai
- Università degli Studi di Cagliari, Dept. Scienze della Vita e dell'Ambiente, University of Cagliari, via Ospedale 72, 09124, Cagliari, Italy.
| |
Collapse
|
30
|
Pireddu R, Sinico C, Ennas G, Schlich M, Valenti D, Murgia S, Marongiu F, Fadda AM, Lai F. The effect of diethylene glycol monoethyl ether on skin penetration ability of diclofenac acid nanosuspensions. Colloids Surf B Biointerfaces 2018; 162:8-15. [DOI: 10.1016/j.colsurfb.2017.11.012] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/24/2017] [Revised: 07/07/2017] [Accepted: 11/04/2017] [Indexed: 02/08/2023]
|
31
|
Manconi M, Manca ML, Caddeo C, Valenti D, Cencetti C, Diez-Sales O, Nacher A, Mir-Palomo S, Terencio MC, Demurtas D, Gomez-Fernandez JC, Aranda FJ, Fadda AM, Matricardi P. Nanodesign of new self-assembling core-shell gellan-transfersomes loading baicalin and in vivo evaluation of repair response in skin. Nanomedicine 2017; 14:569-579. [PMID: 29248674 DOI: 10.1016/j.nano.2017.12.001] [Citation(s) in RCA: 31] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/06/2017] [Revised: 09/14/2017] [Accepted: 12/04/2017] [Indexed: 10/18/2022]
Abstract
Gellan nanohydrogel and phospholipid vesicles were combined to incorporate baicalin in new self-assembling core-shell gellan-transfersomes obtained by an easy, scalable method. The vesicles were small in size (~107 nm) and monodispersed (P.I. ≤ 0.24), forming a viscous system (~24 mPa/s) as compared to transfersomes (~1.6 mPa/s), as confirmed by rheological studies. Gellan was anchored to the bilayer domains through cholesterol, and the polymer chains were distributed onto the outer surface of the bilayer, thus forming a core-shell structure, as suggested by SAXS analyses. The optimal carrier ability of core-shell gellan-transfersomes was established by the high deposition of baicalin in the skin (~11% in the whole skin), especially in the deeper tissue (~8% in the dermis). Moreover, their ability to improve baicalin efficacy in anti-inflammatory and skin repair tests was confirmed in vivo in mice, providing the complete skin restoration and inhibiting all the studied inflammatory markers.
Collapse
Affiliation(s)
- Maria Manconi
- Dept. of Scienze della Vita e dell'Ambiente, University of Cagliari, Cagliari, Italy
| | - Maria Letizia Manca
- Dept. of Scienze della Vita e dell'Ambiente, University of Cagliari, Cagliari, Italy.
| | - Carla Caddeo
- Dept. of Scienze della Vita e dell'Ambiente, University of Cagliari, Cagliari, Italy
| | - Donatella Valenti
- Dept. of Scienze della Vita e dell'Ambiente, University of Cagliari, Cagliari, Italy
| | - Claudia Cencetti
- Dept. of Drug chemistry and technologies, Sapienza, University of Roma, Roma, Italy
| | - Octavio Diez-Sales
- Dept. of Pharmacy and Pharmaceutical Technology and Parasitology, University of Valencia, Burjassot, Valencia, Spain; Institute of Molecular Recognition and Technological Development, Inter-University Institute from Polytechnic University of Valencia and University of Valencia, Spain
| | - Amparo Nacher
- Dept. of Pharmacy and Pharmaceutical Technology and Parasitology, University of Valencia, Burjassot, Valencia, Spain; Institute of Molecular Recognition and Technological Development, Inter-University Institute from Polytechnic University of Valencia and University of Valencia, Spain
| | - Silvia Mir-Palomo
- Dept. of Pharmacy and Pharmaceutical Technology and Parasitology, University of Valencia, Burjassot, Valencia, Spain; Institute of Molecular Recognition and Technological Development, Inter-University Institute from Polytechnic University of Valencia and University of Valencia, Spain
| | | | - Davide Demurtas
- Interdisciplinary Center for Electron Microscopy, Ecole Polytechnique Fédérale de Lausanne, Station 12, Lausanne, Switzerland
| | - Juan Carmelo Gomez-Fernandez
- Dept. of Biochemistry and Molecular Biology A, Regional Campus of International Excellence Campus Mare Nostrum, University of Murcia, Murcia, Spain
| | - Francisco José Aranda
- Dept. of Biochemistry and Molecular Biology A, Regional Campus of International Excellence Campus Mare Nostrum, University of Murcia, Murcia, Spain
| | - Anna Maria Fadda
- Dept. of Scienze della Vita e dell'Ambiente, University of Cagliari, Cagliari, Italy
| | - Pietro Matricardi
- Dept. of Drug chemistry and technologies, Sapienza, University of Roma, Roma, Italy
| |
Collapse
|
32
|
Manca ML, Manconi M, Zaru M, Valenti D, Peris JE, Matricardi P, Maccioni AM, Fadda AM. Glycerosomes: Investigation of role of 1,2-dimyristoyl-sn-glycero-3-phosphatidycholine (DMPC) on the assembling and skin delivery performances. Int J Pharm 2017; 532:401-407. [PMID: 28917990 DOI: 10.1016/j.ijpharm.2017.09.026] [Citation(s) in RCA: 28] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/13/2017] [Revised: 09/07/2017] [Accepted: 09/12/2017] [Indexed: 10/18/2022]
Abstract
Glycerosomes were formulated using 1,2-dimyristoyl-sn-glycero-3-phosphatidycholine (DMPC), diclofenac sodium salt and 10, 20 or 30% glycerol in the water phase, while corresponding liposomes were prepared with the same amount of DMPC and diclofenac, without glycerol. The aim of the present work was to evaluate the effect of the used phospholipid on vesicle features and ability to favour diclofenac skin deposition by comparing these results with those found in previous works performed using hydrogenated soy phosphatidylcholine (P90H) and dipalmitoylphosphatidylcholine (DPPC). Liposomes and glycerosomes were multilamellar, liposomes being smaller (72±6nm). Interactions among glycerol, phospholipids and drug led to the formation of a non-rigid bilayer structure and a variation of the main transition temperature, which shifted to lower temperature. The addition of glycerol led to the formation of more viscous systems (from ∼2.5mPa/s for basic liposomes to ∼5mPa/s for glycerosomes), which improved spread ability of the formulations on the skin.Results obtained in vitro were promising using glycerosomes, irrespective of the amount of glycerol used: the amount of drug, which accumulated into and permeated through the different skin strata, was high and comparable with that obtained using P90H, suggesting that glycerosomes may represent an efficient carrier for both local effect or systemic absorption.
Collapse
Affiliation(s)
- Maria Letizia Manca
- Dept. Scienze della Vita e dell'Ambiente, Sezione Scienze del Farmaco, University of Cagliari, 09124 Cagliari, Italy
| | - Maria Manconi
- Dept. Scienze della Vita e dell'Ambiente, Sezione Scienze del Farmaco, University of Cagliari, 09124 Cagliari, Italy.
| | - Marco Zaru
- Icnodermsrl, Sardegna Ricerche Ed.5, 09010 Pula, Cagliari, Italy
| | - Donatella Valenti
- Dept. Scienze della Vita e dell'Ambiente, Sezione Scienze del Farmaco, University of Cagliari, 09124 Cagliari, Italy
| | - Jose Esteban Peris
- Dept. Farmacia y Tecnologia Farmaceutica, University of Valencia, 46100-Burjassot, Valencia, Spain
| | - Pietro Matricardi
- Dept. di Chimica e Tecnologia Farmaceutica, Sapienza, University of Roma, Roma, Italy
| | - Anna Maria Maccioni
- Dept. Scienze della Vita e dell'Ambiente, Sezione Scienze del Farmaco, University of Cagliari, 09124 Cagliari, Italy
| | - Anna Maria Fadda
- Dept. Scienze della Vita e dell'Ambiente, Sezione Scienze del Farmaco, University of Cagliari, 09124 Cagliari, Italy
| |
Collapse
|
33
|
Schlich M, Lai F, Murgia S, Valenti D, Fadda AM, Sinico C. Needle-free jet injection of intact phospholipid vesicles across the skin: a feasibility study. Biomed Microdevices 2017; 18:67. [PMID: 27422107 DOI: 10.1007/s10544-016-0098-3] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
Abstract
Needle-free liquid jet injectors are devices developed for the delivery of pharmaceutical solutions through the skin. In this paper, we investigated for the first time the ability of these devices to deliver intact lipid vesicles. Diclofenac sodium loaded phospholipid vesicles of two types, namely liposomes and transfersomes, were prepared and fully characterized. The lipid vesicles were delivered through a skin specimen using a jet injector and the collected samples were analyzed to assess vesicle structural integrity, drug retention and release kinetics after the injection. In this regard, data concerning size, size distribution, surface charge of vesicles and bilayer integrity and thickness, before and after the injections, were measured by dynamic light scattering experiments, cryo-electron microscopy, and X-ray scattering techniques. Finally, the effect of vesicle fast jet injection through the skin on drug release kinetics was checked by in vitro experiments. The retention of the morphological, physico-chemical, and technological features after injection, proved the integrity of vesicles after skin crossing as a high-speed liquid jet. The delivery of undamaged vesicular carriers beneath the skin is of utmost importance to create a controlled release drug depot in the hypoderm, which may be beneficial for several localized therapies. Overall results reported in this paper may broaden the range of application of liquid jet injectors to lipid vesicle based formulations thus combining beneficial performance of painless devices with those of liposomal drug delivery systems.
Collapse
Affiliation(s)
- Michele Schlich
- Department Scienze della Vita e dell'Ambiente, University of Cagliari, Via Ospedale 72, 09124, Cagliari, Italy
| | - Francesco Lai
- Department Scienze della Vita e dell'Ambiente, University of Cagliari, Via Ospedale 72, 09124, Cagliari, Italy
| | - Sergio Murgia
- Department Scienze Chimiche e Geologiche, University of Cagliari, S.S. 554 Bivio Sestu, 09042 Monserrato, Cagliari, Italy
| | - Donatella Valenti
- Department Scienze della Vita e dell'Ambiente, University of Cagliari, Via Ospedale 72, 09124, Cagliari, Italy
| | - Anna Maria Fadda
- Department Scienze della Vita e dell'Ambiente, University of Cagliari, Via Ospedale 72, 09124, Cagliari, Italy
| | - Chiara Sinico
- Department Scienze della Vita e dell'Ambiente, University of Cagliari, Via Ospedale 72, 09124, Cagliari, Italy.
| |
Collapse
|
34
|
Manconi M, Manca ML, Valenti D, Escribano E, Hillaireau H, Fadda AM, Fattal E. Chitosan and hyaluronan coated liposomes for pulmonary administration of curcumin. Int J Pharm 2017; 525:203-210. [DOI: 10.1016/j.ijpharm.2017.04.044] [Citation(s) in RCA: 74] [Impact Index Per Article: 10.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/06/2017] [Revised: 04/11/2017] [Accepted: 04/18/2017] [Indexed: 11/30/2022]
|
35
|
Sinico C, Pireddu R, Pini E, Valenti D, Caddeo C, Fadda AM, Lai F. Enhancing Topical Delivery of Resveratrol through a Nanosizing Approach. Planta Med 2017; 83:476-481. [PMID: 27220078 DOI: 10.1055/s-0042-103688] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/05/2023]
Abstract
Resveratrol is a naturally occurring polyphenol with strong antioxidant and free radical scavenging properties, recently proposed as a therapeutic agent for skin diseases. In this study, we investigated the possibility of improving the dermal bioavailability of the poorly water-soluble drug resveratrol by nanocrystal technology. To this purpose, nanosuspensions were prepared by the wet media milling technique, using Poloxamer 188 or Tween 80 as stabilizers, and characterized by means of both solid state and morphological and dimensional studies. All analytical data demonstrated that neither a modification of the drug crystalline pattern nor the isomerization of the trans double bond were observed after the wet media milling particle size reduction process, which produced rounded and smooth nanocrystals with a mean diameter ranging between 0.2-0.3 µm. Resveratrol skin delivery from nanosuspension formulations was evaluated by the pig ear skin model via tape stripping. Results of the experiments showed that after application of nanosuspension formulations, higher amounts of resveratrol could penetrate the skin at deeper levels compared to drug coarse suspensions. The antioxidant activity of resveratrol in nanocrystals was assessed by the DPPH assay, which demonstrated that the size reduction process as well as the formulation compositions did not modify the drug antioxidant activity.
Collapse
Affiliation(s)
- Chiara Sinico
- Dept. Scienze della Vita e dell'Ambiente, Sezione di Scienze del Farmaco, University of Cagliari, Cagliari, Italy
| | - Rosa Pireddu
- Dept. Scienze della Vita e dell'Ambiente, Sezione di Scienze del Farmaco, University of Cagliari, Cagliari, Italy
| | - Elena Pini
- Dept. Scienze Farmaceutiche, Sezione di Chimica Generale e Organica "A. Marchesini", University of Milan, Milan, Italy
| | - Donatella Valenti
- Dept. Scienze della Vita e dell'Ambiente, Sezione di Scienze del Farmaco, University of Cagliari, Cagliari, Italy
| | - Carla Caddeo
- Dept. Scienze della Vita e dell'Ambiente, Sezione di Scienze del Farmaco, University of Cagliari, Cagliari, Italy
| | - Anna Maria Fadda
- Dept. Scienze della Vita e dell'Ambiente, Sezione di Scienze del Farmaco, University of Cagliari, Cagliari, Italy
| | - Francesco Lai
- Dept. Scienze della Vita e dell'Ambiente, Sezione di Scienze del Farmaco, University of Cagliari, Cagliari, Italy
| |
Collapse
|
36
|
Vitonyte J, Manca ML, Caddeo C, Valenti D, Peris JE, Usach I, Nacher A, Matos M, Gutiérrez G, Orrù G, Fernàndez-Busquets X, Fadda AM, Manconi M. Bifunctional viscous nanovesicles co-loaded with resveratrol and gallic acid for skin protection against microbial and oxidative injuries. Eur J Pharm Biopharm 2017; 114:278-287. [PMID: 28192250 DOI: 10.1016/j.ejpb.2017.02.004] [Citation(s) in RCA: 38] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/12/2016] [Revised: 02/01/2017] [Accepted: 02/08/2017] [Indexed: 11/25/2022]
Abstract
Resveratrol and gallic acid were co-loaded in phospholipid vesicles aiming at protecting the skin from external injuries, such as oxidative stress and microbial infections. Liposomes were prepared using biocompatible phospholipids dispersed in water. To improve vesicle stability and applicability, the phospholipids and the phenols were dispersed in water/propylene glycol or water/glycerol, thus obtaining PEVs and glycerosomes, respectively. The vesicles were characterized by size, morphology, physical stability, and their therapeutic efficacy was investigated in vitro. The vesicles were spherical, unilamellar and small in size: liposomes and glycerosomes were around 70nm in diameter, while PEVs were larger (∼170nm). The presence of propylene glycol or glycerol increased the viscosity of the vesicle systems, positively affecting their stability. The ability of the vesicles to promote the accumulation of the phenols (especially gallic acid) in the skin was demonstrated, as well as their low toxicity and great ability to protect keratinocytes and fibroblasts from oxidative damage. Additionally, an improvement of the antimicrobial activity of the phenols was shown against different skin pathogens. The co-loading of resveratrol and gallic acid in modified phospholipid vesicles represents an innovative, bifunctional tool for preventing and treating skin affections.
Collapse
Affiliation(s)
- Justina Vitonyte
- Dept. of Clinical Pharmacy, Lithuanian University of Health Sciences, Sukileliu pr. 13, Kaunas, Lithuania
| | - Maria Letizia Manca
- Dept. Scienze della Vita e dell'Ambiente, University of Cagliari, Via Ospedale 72, 09124 Cagliari, Italy
| | - Carla Caddeo
- Dept. Scienze della Vita e dell'Ambiente, University of Cagliari, Via Ospedale 72, 09124 Cagliari, Italy.
| | - Donatella Valenti
- Dept. Scienze della Vita e dell'Ambiente, University of Cagliari, Via Ospedale 72, 09124 Cagliari, Italy
| | - Josè Esteban Peris
- Dept. of Pharmacy and Pharmaceutical Technology, University of Valencia, Avda Vicente Andrés Estellés s/n, 46100-Burjassot, Valencia, Spain
| | - Iris Usach
- Dept. of Pharmacy and Pharmaceutical Technology, University of Valencia, Avda Vicente Andrés Estellés s/n, 46100-Burjassot, Valencia, Spain
| | - Amparo Nacher
- Dept. of Pharmacy and Pharmaceutical Technology, University of Valencia, Avda Vicente Andrés Estellés s/n, 46100-Burjassot, Valencia, Spain; Instituto de Reconocimiento Molecular y Desarrollo Tecnológico, Centro Mixto Universidad Politécnica de Valencia-Universidad de Valencia, Spain
| | - Maria Matos
- Dept. Ingeniería Química y Tecnología del Medio Ambiente, University of Oviedo, C/ Julián Clavería 8, 33006 Oviedo, Spain
| | - Gemma Gutiérrez
- Dept. Ingeniería Química y Tecnología del Medio Ambiente, University of Oviedo, C/ Julián Clavería 8, 33006 Oviedo, Spain
| | - Germano Orrù
- Dept. of Surgical Science, University of Cagliari, Molecular Biology Service Lab (MBS), via Ospedale 40, 09124 Cagliari, Italy
| | - Xavier Fernàndez-Busquets
- Nanomalaria Group, Institute for Bioengineering of Catalonia (IBEC), Baldiri Reixac 10-12, Barcelona E08028, Spain; Barcelona Institute for Global Health (ISGlobal), Barcelona Centre for International Health Research (CRESIB, Hospital Clínic-Universitat de Barcelona), Rosselló 149-153, Barcelona E08036, Spain
| | - Anna Maria Fadda
- Dept. Scienze della Vita e dell'Ambiente, University of Cagliari, Via Ospedale 72, 09124 Cagliari, Italy
| | - Maria Manconi
- Dept. Scienze della Vita e dell'Ambiente, University of Cagliari, Via Ospedale 72, 09124 Cagliari, Italy
| |
Collapse
|
37
|
Salman A, Simoneau E, Hassanain M, Chaudhury P, Boucher LM, Valenti D, Cabrera T, Nudo C, Metrakos P. Combined sorafenib and yttrium-90 radioembolization for the treatment of advanced hepatocellular carcinoma. ACTA ACUST UNITED AC 2016; 23:e472-e480. [PMID: 27803608 DOI: 10.3747/co.23.2827] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
BACKGROUND AND AIMS In this pilot study, we assessed the safety and tolerability of combining sorafenib with 90Y radioembolization for the treatment of unresectable hepatocellular carcinoma (hcc). METHODS The study, conducted prospectively during 2009-2012, included eligible patients with unresectable hcc and a life expectancy of at least 12 weeks. Each patient received sorafenib (400 mg twice daily) for 6-8 weeks before 90Y treatment. Safety and tolerability were assessed. RESULTS Of the 40 patients enrolled, 29 completed treatment (combined therapy). In the initial cohort, the most common cause of hcc was hepatitis C (32.5%), and most patients were staged Child A (82.5%). The 29 patients who completed the study had similar baseline characteristics. Grades 1 and 2 toxicities accounted for 77.8% of all adverse events reported. The most common toxicities reported were fatigue (19.0%), alteration in liver function (7.9%), and diarrhea (6.3%). There were 12 grade 3 and 2 grade 4 toxicity events reported. One patient died of liver failure within 30 days after treatment. During the study, the sorafenib dose was reduced in 6 patients (20.7%), and sorafenib had to be interrupted in 4 patients (13.8%) and discontinued in 4 patients (13.8%). The disease control rate was 72.4% per the modified Response Evaluation Criteria in Solid Tumors, and tumour necrosis was observed in 82.8% of patients. Overall survival in patients undergoing combined therapy was 12.4 months. CONCLUSIONS Preliminary results demonstrate the safety and tolerability of combining 90Y radioembolization and sorafenib for advanced hcc. A larger prospective study is needed to determine the extent of the survival benefit.
Collapse
Affiliation(s)
- A Salman
- Department of Surgery, Division of Hepatopancreatobiliary and Transplant Surgery, McGill University, Montreal, QC
| | - E Simoneau
- Department of Surgery, Division of Hepatopancreatobiliary and Transplant Surgery, McGill University, Montreal, QC
| | - M Hassanain
- Department of Oncology, McGill University, Montreal, QC; Department of Surgery, King Saud University, Riyadh, Saudi Arabia
| | - P Chaudhury
- Department of Surgery, Division of Hepatopancreatobiliary and Transplant Surgery, McGill University, Montreal, QC; Department of Oncology, McGill University, Montreal, QC
| | - L M Boucher
- Department of Radiology, Division of Interventional Radiology, McGill University, Montreal, QC
| | - D Valenti
- Department of Radiology, Division of Interventional Radiology, McGill University, Montreal, QC
| | - T Cabrera
- Department of Radiology, Division of Interventional Radiology, McGill University, Montreal, QC
| | - C Nudo
- Department of Medicine, Division of Hepatology, McGill University, Montreal, QC
| | - P Metrakos
- Department of Surgery, Division of Hepatopancreatobiliary and Transplant Surgery, McGill University, Montreal, QC; Department of Oncology, McGill University, Montreal, QC
| |
Collapse
|
38
|
Manca ML, Cencetti C, Matricardi P, Castangia I, Zaru M, Sales OD, Nacher A, Valenti D, Maccioni AM, Fadda AM, Manconi M. Glycerosomes: Use of hydrogenated soy phosphatidylcholine mixture and its effect on vesicle features and diclofenac skin penetration. Int J Pharm 2016; 511:198-204. [PMID: 27418567 DOI: 10.1016/j.ijpharm.2016.07.009] [Citation(s) in RCA: 39] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/22/2016] [Revised: 07/05/2016] [Accepted: 07/08/2016] [Indexed: 10/21/2022]
Abstract
In this work, diclofenac was encapsulated, as sodium salt, in glycerosomes containing 10, 20 or 30% of glycerol in the water phase with the aim to ameliorate its topical efficacy. Taking into account previous findings, glycerosome formulation was modified, in terms of economic suitability, using a cheap and commercially available mixture of hydrogenated soy phosphatidylcholine (P90H). P90H glycerosomes were spherical and multilamellar; photon correlation spectroscopy showed that obtained vesicles were ∼131nm, slightly larger and more polydispersed than those made with dipalmitoylphosphatidylcholine (DPPC) but, surprisingly, they were able to ameliorate the local delivery of diclofenac, which was improved with respect to previous findings, in particular using glycerosomes containing high amount of glycerol (20 and 30%). Finally, this drug delivery system showed a high in vitro biocompatibility toward human keratinocytes.
Collapse
Affiliation(s)
- Maria Letizia Manca
- Dept. Scienze della Vita e dell'Ambiente, Drug Science Division, University of Cagliari, 09124 Cagliari, Italy
| | - Claudia Cencetti
- Dept. Chemistry and Drug Technologies, Sapienza, University of Roma, Roma, Italy
| | - Pietro Matricardi
- Dept. Chemistry and Drug Technologies, Sapienza, University of Roma, Roma, Italy.
| | - Ines Castangia
- Dept. Scienze della Vita e dell'Ambiente, Drug Science Division, University of Cagliari, 09124 Cagliari, Italy
| | - Marco Zaru
- Icnoderm srl, Sardegna Ricerche Ed.5, 09010 Pula, Cagliari, Italy
| | - Octavio Diez Sales
- Dept. Farmacia y Tecnologia Farmaceutica, University of Valencia, 46100-Burjassot, Valencia, Spain
| | - Amparo Nacher
- Dept. Farmacia y Tecnologia Farmaceutica, University of Valencia, 46100-Burjassot, Valencia, Spain
| | - Donatella Valenti
- Dept. Scienze della Vita e dell'Ambiente, Drug Science Division, University of Cagliari, 09124 Cagliari, Italy
| | - Anna Maria Maccioni
- Dept. Scienze della Vita e dell'Ambiente, Drug Science Division, University of Cagliari, 09124 Cagliari, Italy
| | - Anna Maria Fadda
- Dept. Scienze della Vita e dell'Ambiente, Drug Science Division, University of Cagliari, 09124 Cagliari, Italy
| | - Maria Manconi
- Dept. Scienze della Vita e dell'Ambiente, Drug Science Division, University of Cagliari, 09124 Cagliari, Italy
| |
Collapse
|
39
|
Caddeo C, Nacher A, Vassallo A, Armentano MF, Pons R, Fernàndez-Busquets X, Carbone C, Valenti D, Fadda AM, Manconi M. Effect of quercetin and resveratrol co-incorporated in liposomes against inflammatory/oxidative response associated with skin cancer. Int J Pharm 2016; 513:153-163. [PMID: 27609664 DOI: 10.1016/j.ijpharm.2016.09.014] [Citation(s) in RCA: 94] [Impact Index Per Article: 11.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/27/2016] [Revised: 09/01/2016] [Accepted: 09/04/2016] [Indexed: 10/21/2022]
Abstract
The present investigation reports the development of liposomes for the co-delivery of naturally occurring polyphenols, namely quercetin and resveratrol. Small, spherical, uni/bilamellar vesicles were produced, as demonstrated by light scattering, cryo-TEM, SAXS. The incorporation of quercetin and resveratrol in liposomes did not affect their intrinsic antioxidant activity, as DPPH radical was almost completely inhibited. The cellular uptake of the polyphenols was higher when they were formulated in liposomes, and especially when co-loaded rather than as single agents, which resulted in a superior ability to scavenge ROS in fibroblasts. The in vivo efficacy of the polyphenols in liposomes was assessed in a mouse model of skin lesion. The topical administration of liposomes led to a remarkable amelioration of the tissue damage, with a significant reduction of oedema and leukocyte infiltration. Therefore, the proposed approach based on polyphenol vesicular formulation may be of value in the treatment of inflammation/oxidative stress associated with pre-cancerous/cancerous skin lesions.
Collapse
Affiliation(s)
- Carla Caddeo
- Dept. of Science della Vita e dell'Ambiente, Sezione di Scienze del Farmaco, University of Cagliari, Via Ospedale 72, 09124 Cagliari, Italy.
| | - Amparo Nacher
- Dept. of Pharmacy and Pharmaceutical Technology, University of Valencia, Avda Vicente Andrés Estellés s/n, 46100 Burjassot, Valencia, Spain; Institute of Molecular Recognition and Technological Development, Inter-Universitary Institute from Polytechnic University of Valencia and University of Valencia, Spain
| | - Antonio Vassallo
- Dept. of Science, University of Basilicata, Viale dell'Ateneo Lucano 10, 85100 Potenza, Italy
| | | | - Ramon Pons
- Dept. of Tecnologia Química i de Tensioactius, Institut de Química Avançada de Catalunya (IQAC-CSIC), 08034 Barcelona, Spain
| | - Xavier Fernàndez-Busquets
- Nanomalaria Group, Institute for Bioengineering of Catalonia (IBEC), Baldiri Reixac 10-12, Barcelona E08028, Spain; Barcelona Institute for Global Health (ISGlobal), Barcelona Centre for International Health Research (CRESIB, Hospital Clínic-Universitat de Barcelona), Rosselló 149-153, Barcelona E08036, Spain
| | - Claudia Carbone
- Dept. of Scienze del Farmaco, University of Catania, Viale A. Doria 6, 95125 Catania, Italy
| | - Donatella Valenti
- Dept. of Science della Vita e dell'Ambiente, Sezione di Scienze del Farmaco, University of Cagliari, Via Ospedale 72, 09124 Cagliari, Italy
| | - Anna Maria Fadda
- Dept. of Science della Vita e dell'Ambiente, Sezione di Scienze del Farmaco, University of Cagliari, Via Ospedale 72, 09124 Cagliari, Italy
| | - Maria Manconi
- Dept. of Science della Vita e dell'Ambiente, Sezione di Scienze del Farmaco, University of Cagliari, Via Ospedale 72, 09124 Cagliari, Italy
| |
Collapse
|
40
|
Melis V, Manca ML, Bullita E, Tamburini E, Castangia I, Cardia MC, Valenti D, Fadda AM, Peris JE, Manconi M. Inhalable polymer-glycerosomes as safe and effective carriers for rifampicin delivery to the lungs. Colloids Surf B Biointerfaces 2016; 143:301-308. [DOI: 10.1016/j.colsurfb.2016.03.044] [Citation(s) in RCA: 37] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/02/2016] [Revised: 03/13/2016] [Accepted: 03/15/2016] [Indexed: 01/12/2023]
|
41
|
Sandoval D, Valenti D, Bateman T, Norris V, Mlady G, Selwyn R. SU-F-P-06: Moving From Computed Radiography to Digital Radiography: A Collaborative Approach to Improve Image Quality. Med Phys 2016. [DOI: 10.1118/1.4955713] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
42
|
Montenegro L, Lai F, Offerta A, Sarpietro MG, Micicchè L, Maccioni AM, Valenti D, Fadda AM. From nanoemulsions to nanostructured lipid carriers: A relevant development in dermal delivery of drugs and cosmetics. J Drug Deliv Sci Technol 2016. [DOI: 10.1016/j.jddst.2015.10.003] [Citation(s) in RCA: 59] [Impact Index Per Article: 7.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
|
43
|
Pireddu R, Caddeo C, Valenti D, Marongiu F, Scano A, Ennas G, Lai F, Fadda AM, Sinico C. Diclofenac acid nanocrystals as an effective strategy to reduce in vivo skin inflammation by improving dermal drug bioavailability. Colloids Surf B Biointerfaces 2016; 143:64-70. [PMID: 26998867 DOI: 10.1016/j.colsurfb.2016.03.026] [Citation(s) in RCA: 45] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/22/2016] [Revised: 03/08/2016] [Accepted: 03/09/2016] [Indexed: 11/29/2022]
Abstract
In this work a diclofenac acid nanosuspension formulation was produced as a novel approach for the treatment of skin inflammation. Drug nanocrystals, prepared by the wet media milling technique and stabilized using Poloxamer 188, were characterized by different techniques: scanning electron microscopy, differential scanning calorimetry, X-ray powder diffractometry, Fourier transform infrared spectroscopy and photon correlation spectroscopy. The ability of nanocrystals to improve dermal drug bioavailability was investigated ex vivo by using Franz diffusion vertical cells and mouse skin, in comparison with both diclofenac acid coarse suspensions and a commercial formulation. The topical anti-inflammatory activity of the drug nanosuspension was assessed in vivo by testing its effect compared to common inflammatory endpoints: i.e. the inhibition of chemically induced oedema and leucocyte infiltration (reflected in myeloperoxidase activity). Following the milling procedure, diclofenac nanocrystals exhibited a mean diameter of approximately 279nm, a low polydispersity index (∼0.17) and maintained the same polymorphic form of the starting bulk powder. When the drug nanosuspension was applied on the mouse skin it produced a higher accumulation of diclofenac in the skin compared to both the coarse suspensions and the commercial formulation, as demonstrated by ex vivo transdermal delivery experiments. Moreover, the nanosuspension provided an in vivo oedema inhibition of 50%, which was not statistically different from the commercial formulation. On the contrary, the nanosuspension showed a higher inhibition of myeloperoxidase activity in the damaged tissue (86%) than the commercial formulation (16%).
Collapse
Affiliation(s)
- Rosa Pireddu
- Dept. Scienze della Vita e dell'Ambiente, University of Cagliari, via Ospedale 72, 09124 Cagliari, Italy
| | - Carla Caddeo
- Dept. Scienze della Vita e dell'Ambiente, University of Cagliari, via Ospedale 72, 09124 Cagliari, Italy
| | - Donatella Valenti
- Dept. Scienze della Vita e dell'Ambiente, University of Cagliari, via Ospedale 72, 09124 Cagliari, Italy
| | - Francesca Marongiu
- Dept. Scienze della Vita e dell'Ambiente, University of Cagliari, via Ospedale 72, 09124 Cagliari, Italy
| | - Alessandra Scano
- Dept. Scienze Chimiche e Geologiche, Unita di Ricerca del Consorzio Nazionale di Scienze e Tecnologie dei Materiali (INSTM), University of Cagliari, SS 554 Bivio Sestu, 09042 Monserrato (CA), Italy
| | - Guido Ennas
- Dept. Scienze Chimiche e Geologiche, Unita di Ricerca del Consorzio Nazionale di Scienze e Tecnologie dei Materiali (INSTM), University of Cagliari, SS 554 Bivio Sestu, 09042 Monserrato (CA), Italy
| | - Francesco Lai
- Dept. Scienze della Vita e dell'Ambiente, University of Cagliari, via Ospedale 72, 09124 Cagliari, Italy.
| | - Anna Maria Fadda
- Dept. Scienze della Vita e dell'Ambiente, University of Cagliari, via Ospedale 72, 09124 Cagliari, Italy
| | - Chiara Sinico
- Dept. Scienze della Vita e dell'Ambiente, University of Cagliari, via Ospedale 72, 09124 Cagliari, Italy
| |
Collapse
|
44
|
Corli O, Floriani I, Roberto A, Montanari M, Galli F, Greco MT, Caraceni A, Kaasa S, Dragani TA, Azzarello G, Luzzani M, Cavanna L, Bandieri E, Gamucci T, Lipari G, Di Gregorio R, Valenti D, Reale C, Pavesi L, Iorno V, Crispino C, Pacchioni M, Apolone G. Are strong opioids equally effective and safe in the treatment of chronic cancer pain? A multicenter randomized phase IV 'real life' trial on the variability of response to opioids. Ann Oncol 2016; 27:1107-1115. [PMID: 26940689 DOI: 10.1093/annonc/mdw097] [Citation(s) in RCA: 70] [Impact Index Per Article: 8.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/04/2015] [Accepted: 02/16/2016] [Indexed: 11/14/2022] Open
Abstract
BACKGROUND Guidelines tend to consider morphine and morphine-like opioids comparable and interchangeable in the treatment of chronic cancer pain, but individual responses can vary. This study compared the analgesic efficacy, changes of therapy and safety profile over time of four strong opioids given for cancer pain. PATIENT AND METHODS In this four-arm multicenter, randomized, comparative, of superiority, phase IV trial, oncological patients with moderate to severe pain requiring WHO step III opioids were randomly assigned to receive oral morphine or oxycodone or transdermal fentanyl or buprenorphine for 28 days. At each visit, pain intensity, modifications of therapy and adverse drug reactions (ADRs) were recorded. The primary efficacy end point was the proportion of nonresponders, meaning patients with worse or unchanged average pain intensity (API) between the first and last visit, measured on a 0-10 numerical rating scale. (NCT01809106). RESULTS Forty-four centers participated in the trial and recruited 520 patients. Worst pain intensity and API decreased over 4 weeks with no significant differences between drugs. Nonresponders ranged from 11.5% (morphine) to 14.4% (buprenorphine). Appreciable changes were made in the treatment schedules over time. Each group required increases in the daily dose, from 32.7% (morphine) to 121.2% (transdermal fentanyl). Patients requiring adjuvant analgesics ranged from 68.9% (morphine) to 81.6% (oxycodone), switches varied from 22.1% (morphine) to 12% (oxycodone), discontinuation of treatment from 27% ( morphine) to 14.5% (fentanyl). ADRs were similar except for effects on the nervous system, which significantly prevailed with morphine. CONCLUSION The main findings were the similarity in pain control, response rates and main adverse reactions among opioids. Changes in therapy schedules were notable over time. A considerable proportion of patients were nonresponders or poor responders. CLINICAL TRIAL REGISTRATION NCT01809106 (https://clinicaltrials.gov/ct2/show/NCT01809106?term=cerp&rank=2).
Collapse
Affiliation(s)
- O Corli
- Department of Oncology, Unità di Ricerca nel Dolore e Cure Palliative.
| | - I Floriani
- Department of Oncology, Laboratorio di Ricerca Clinica, IRCCS-Istituto di Ricerche Farmacologiche Mario Negri, Milan
| | - A Roberto
- Department of Oncology, Unità di Ricerca nel Dolore e Cure Palliative
| | - M Montanari
- Department of Oncology, Unità di Ricerca nel Dolore e Cure Palliative
| | - F Galli
- Department of Oncology, Laboratorio di Ricerca Clinica, IRCCS-Istituto di Ricerche Farmacologiche Mario Negri, Milan
| | - M T Greco
- Department of Oncology, Unità di Ricerca nel Dolore e Cure Palliative; Department of Statistics, Università di Milano, Milan
| | - A Caraceni
- Palliative Care Complex Structure, Terapia del dolore e Riabilitazione, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| | - S Kaasa
- Department of Cancer Research and Molecular Medicine, Faculty of Medicine, Norwegian University of Science and Technology, Norway
| | - T A Dragani
- S.S.D. Epidemiology, Genetics and Pharmacogenomics, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan
| | - G Azzarello
- Department of Hematology and Oncology, Ospedale di U.O.C. di Oncologia Mirano-ASL 13 Regione Veneto, Mirano
| | - M Luzzani
- Department of Orthogeriatrics, S.S.D. Cure Palliative, riabilitazione e stabilizzazione E.O. Ospedali Galliera, Genova
| | - L Cavanna
- Oncology Unit, Ospedale di Piacenza, Piacenza
| | - E Bandieri
- Unit of Supportive and Simultaneous Care, Medical Oncology Division USL, Modena
| | - T Gamucci
- UOC Medical Oncology, Ospedale SS Trinità, Sora
| | - G Lipari
- Palliative Care, P.O. di Salemi-ASP 9, Trapani
| | - R Di Gregorio
- U.O.S Obstetric Anasthesia and Pain Therapy, Opedale Sacro Cuore di Gesù - Fatebenefratelli, Benevento
| | - D Valenti
- Palliative Care Unit, Azienda Ospedaliera Valtellina e Valchiavenna, Morbegno
| | - C Reale
- Department of Cardiovascular Sciences, Respiratory, Nephrological, Anaesthetics and Geriatrics, Policlinico Universitario Umberto I, Rome
| | - L Pavesi
- Unit of Oncology, RCCS-Fondazione Salvatore Maugeri, Pavia
| | - V Iorno
- Centre for Pain Medicine M. TIENGO, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Milan
| | - C Crispino
- UOSD Treatment of Lung Cancer Complications, AO Dei Colli Monaldi Cotugno CTO Ospedale Monaldi, Napoli
| | - M Pacchioni
- Department of Oncology, Ospedale San Raffaele IRCCS, Milan
| | - G Apolone
- Scientific Direction, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| | | |
Collapse
|
45
|
Khankan A, Guzaiz N, Al-Olayan A, Al-Hazmi T, Valenti D, Al-Moaiqel M. Sorafenib in combination with transarterial therapies for hepatocellular carcinoma: is more always better? J Vasc Interv Radiol 2016. [DOI: 10.1016/j.jvir.2015.12.631] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
46
|
Caddeo C, Manconi M, Sinico C, Valenti D, Celia C, Monduzzi M, Fadda A. Penetration Enhancer-Containing Vesicles: Does the Penetration Enhancer Structure Affect Topical Drug Delivery? Curr Drug Targets 2015; 16:1438-47. [DOI: 10.2174/1389450115666140804224024] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/03/2014] [Accepted: 07/24/2014] [Indexed: 11/22/2022]
|
47
|
Kargovsky AV, Chichigina OA, Anashkina EI, Valenti D, Spagnolo B. Relaxation dynamics in the presence of pulse multiplicative noise sources with different correlation properties. Phys Rev E Stat Nonlin Soft Matter Phys 2015; 92:042140. [PMID: 26565201 DOI: 10.1103/physreve.92.042140] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/16/2015] [Indexed: 06/05/2023]
Abstract
The relaxation dynamics of a system described by a Langevin equation with pulse multiplicative noise sources with different correlation properties is considered. The solution of the corresponding Fokker-Planck equation is derived for Gaussian white noise. Moreover, two pulse processes with regulated periodicity are considered as a noise source: the dead-time-distorted Poisson process and the process with fixed time intervals, which is characterized by an infinite correlation time. We find that the steady state of the system is dependent on the correlation properties of the pulse noise. An increase of the noise correlation causes the decrease of the mean value of the solution at the steady state. The analytical results are in good agreement with the numerical ones.
Collapse
Affiliation(s)
- A V Kargovsky
- Faculty of Physics and International Laser Center, Lomonosov Moscow State University, Leninskie Gory, 119992 Moscow, Russia
| | - O A Chichigina
- Faculty of Physics and International Laser Center, Lomonosov Moscow State University, Leninskie Gory, 119992 Moscow, Russia
| | - E I Anashkina
- Faculty of Physics, Lomonosov Moscow State University, Leninskie Gory, 119992 Moscow, Russia and Dipartimento di Fisica e Chimica, Group of Interdisciplinary Theoretical Physics, Università di Palermo, Viale delle Scienze, Edificio 18, 90128 Palermo, Italy
| | - D Valenti
- Dipartimento di Fisica e Chimica, Group of Interdisciplinary Theoretical Physics, Università di Palermo and CNISM, Unità di Palermo, Viale delle Scienze, Edificio 18, 90128 Palermo, Italy and Istituto Nazionale di Fisica Nucleare, Sezione di Catania, Italy
| | - B Spagnolo
- Dipartimento di Fisica e Chimica, Group of Interdisciplinary Theoretical Physics, Università di Palermo and CNISM, Unità di Palermo, Viale delle Scienze, Edificio 18, 90128 Palermo, Italy and Istituto Nazionale di Fisica Nucleare, Sezione di Catania, Italy
| |
Collapse
|
48
|
Manca ML, Castangia I, Zaru M, Nácher A, Valenti D, Fernàndez-Busquets X, Fadda AM, Manconi M. Development of curcumin loaded sodium hyaluronate immobilized vesicles (hyalurosomes) and their potential on skin inflammation and wound restoring. Biomaterials 2015; 71:100-109. [PMID: 26321058 DOI: 10.1016/j.biomaterials.2015.08.034] [Citation(s) in RCA: 139] [Impact Index Per Article: 15.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/24/2015] [Revised: 08/08/2015] [Accepted: 08/14/2015] [Indexed: 02/02/2023]
Abstract
In the present work new highly biocompatible nanovesicles were developed using polyanion sodium hyaluronate to form polymer immobilized vesicles, so called hyalurosomes. Curcumin, at high concentration was loaded into hyalurosomes and physico-chemical properties and in vitro/in vivo performances of the formulations were compared to those of liposomes having the same lipid and drug content. Vesicles were prepared by direct addition of dispersion containing the polysaccharide sodium hyaluronate and the polyphenol curcumin to a commercial mixture of soy phospholipids, thus avoiding the use of organic solvents. An extensive study was carried out on the physico-chemical features and properties of curcumin-loaded hyalurosomes and liposomes. Cryogenic transmission electron microscopy and small-angle X-ray scattering showed that vesicles were spherical, uni- or oligolamellar and small in size (112-220 nm). The in vitro percutaneous curcumin delivery studies on intact skin showed an improved ability of hyalurosomes to favour a fast drug deposition in the whole skin. Hyalurosomes as well as liposomes were biocompatible, protected in vitro human keratinocytes from oxidative stress damages and promoted tissue remodelling through cellular proliferation and migration. Moreover, in vivo tests underlined a good effectiveness of curcumin-loaded hyalurosomes to counteract 12-O-tetradecanoilphorbol (TPA)-produced inflammation and injuries, diminishing oedema formation, myeloperoxydase activity and providing an extensive skin reepithelization. Thanks to the one-step and environmentally-friendly preparation method, component biocompatibility and safety, good in vitro and in vivo performances, the hyalurosomes appear as promising nanocarriers for cosmetic and pharmaceutical applications.
Collapse
Affiliation(s)
- M L Manca
- Dept. Scienze della Vita e dell'Ambiente, University of Cagliari, Via Ospedale 72, 09124, Cagliari, Italy
| | - I Castangia
- Dept. Scienze della Vita e dell'Ambiente, University of Cagliari, Via Ospedale 72, 09124, Cagliari, Italy
| | - M Zaru
- Instituto de Reconocimiento Molecular y Desarrollo Tecnológico, Centro Mixto Universidad Politécnica de Valencia-Universidad de Valencia, Spain
| | - A Nácher
- Icnoderm Srl, Sardegna Ricerche Ed.5, Pula, Cagliari, 09010, Italy; Dept. of Pharmacy and Pharmaceutical Technology, University of Valencia, Avda Vicente Andrés Estellés s/n, 46100-Burjassot, Valencia, Spain
| | - D Valenti
- Dept. Scienze della Vita e dell'Ambiente, University of Cagliari, Via Ospedale 72, 09124, Cagliari, Italy
| | - X Fernàndez-Busquets
- Nanomalaria Unit, Institute for Bioengineering of Catalonia (IBEC), Barcelona, Spain; Barcelona Institute for Global Health (ISGlobal, Hospital Clínic-Universitat de Barcelona), Spain; Nanoscience and Nanotechnology Institute (IN2UB), University of Barcelona, Spain
| | - A M Fadda
- Dept. Scienze della Vita e dell'Ambiente, University of Cagliari, Via Ospedale 72, 09124, Cagliari, Italy
| | - M Manconi
- Dept. Scienze della Vita e dell'Ambiente, University of Cagliari, Via Ospedale 72, 09124, Cagliari, Italy.
| |
Collapse
|
49
|
Simoneau E, Hassanain M, Shaheen M, Aljiffry M, Molla N, Chaudhury P, Anil S, Khashper A, Valenti D, Metrakos P. Portal vein embolization and its effect on tumour progression for colorectal cancer liver metastases. Br J Surg 2015; 102:1240-9. [PMID: 26109487 DOI: 10.1002/bjs.9872] [Citation(s) in RCA: 40] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2014] [Revised: 05/08/2015] [Accepted: 05/14/2015] [Indexed: 12/26/2022]
Abstract
BACKGROUND The aim of this study was to evaluate the long-term outcomes of patients with colorectal cancer liver metastasis (CRCLM) exhibiting disease progression after portal vein embolization (PVE). METHODS Patients with CRCLM requiring PVE before hepatectomy between 2003 and 2014 were included. Clinical variables, and liver and tumour volumes determined by three-dimensional CT volumetry were assessed before and after PVE. Overall and disease-free survival data were obtained. Univariable and multivariable logistic regression analyses were performed to identify predictors of tumour progression after PVE. RESULTS Of 141 patients who underwent PVE, 93 (66.0 per cent) had tumour progression and 17 (12.1 per cent) developed new contralateral lesions. Significantly fewer patients had resectable disease in the group with disease progression than among those with stable disease: 43 (46 per cent) of 93 versus 36 (75 per cent) of 48 respectively (P = 0.001). Median survival was similar in patients with and without tumour growth after PVE: 22.5 versus 26.0 months for patients with unresectable tumours (P = 0.706) and 46.2 versus 52.2 months for those with resectable disease (P = 0.953). However, disease-free survival for patients with tumour progression after PVE was shorter than that for patients with stable disease (6.0 versus 20.2 months; P = 0.045). Response to neoadjuvant chemotherapy was the only significant factor associated with tumour progression in multivariable analysis. CONCLUSION Tumour progression after PVE did not affect overall survival, but patients with resected tumours who had tumour growth after embolization experienced earlier recurrence. A borderline response to neoadjuvant chemotherapy seemed to be associated with tumour progression after PVE.
Collapse
Affiliation(s)
- E Simoneau
- Department of Surgery, Division of Hepatopancreatobiliary Surgery, McGill University, Montreal, Quebec, Canada
| | - M Hassanain
- Division of Oncology, Department of Surgery, McGill University, Montreal, Quebec, Canada.,Department of Surgery, King Saud University, Riyadh, Saudi Arabia
| | - M Shaheen
- Department of Surgery, Division of Hepatopancreatobiliary Surgery, McGill University, Montreal, Quebec, Canada
| | - M Aljiffry
- Department of Surgery, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia
| | - N Molla
- Department of Radiology, McGill University, Montreal, Quebec, Canada
| | - P Chaudhury
- Department of Surgery, Division of Hepatopancreatobiliary Surgery, McGill University, Montreal, Quebec, Canada.,Division of Oncology, Department of Surgery, McGill University, Montreal, Quebec, Canada
| | - S Anil
- Department of Surgery, King Saud University, Riyadh, Saudi Arabia
| | - A Khashper
- Department of Radiology, McGill University, Montreal, Quebec, Canada
| | - D Valenti
- Department of Radiology, McGill University, Montreal, Quebec, Canada
| | - P Metrakos
- Department of Surgery, Division of Hepatopancreatobiliary Surgery, McGill University, Montreal, Quebec, Canada
| |
Collapse
|
50
|
Lee MJ, Valenti D, de Gregorio MA, Minocha J, Rimon U, Pellerin O. The CIRSE Retrievable IVC Filter Registry: Retrieval Success Rates in Practice. Cardiovasc Intervent Radiol 2015; 38:1502-7. [PMID: 25933644 DOI: 10.1007/s00270-015-1112-5] [Citation(s) in RCA: 47] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/08/2014] [Accepted: 03/30/2015] [Indexed: 12/19/2022]
Abstract
CIRSE established a registry of retrievable filter use with the primary aim of determining the success of IVC Filter retrieval and associated complications. Secondary endpoints included filter indications, imaging strategies before retrieval, filter dwell times, and anticoagulation status. A web-based electronic registry was hosted between 01/12/2010 and 30/06/2012. Data entry occurred at the date of IVC filter retrieval and included items such as filter type, indication for filter insertion, access route, dwell time, retrieval success, complications, reasons for failed retrieval, and anticoagulation status. 671 filter retrievals were entered (male:female 333:295, mean age 55, median 57). Retrieval data were not entered in 43/671 leaving 628 patients for analysis. The 4 commonest retrievable filters used were the Celect in 182 patients, the OPTEASE in 161, ALN in 120, and Gunther Tulip in 98. Filters were inserted for absolute indications 40%, relative indications in 31%, and prophylactic in 24%, with 5% missing. Mean filter dwell time was 90 days. Filters were successfully retrieved in 576/628 patients (92%). The mean dwell time for successful retrievals was 85 days versus 145 days for unsuccessful retrievals (p = 0.001). Major complications occurred in 2 patients (0.03%). In summary, the CIRSE retrievable filter registry demonstrates a retrieval rate of 92% across a range of filter types, with a low major complication rate, reflecting current practice. There is an increase in trend of retrievable filter use for relative and prophylactic indications.
Collapse
Affiliation(s)
- M J Lee
- The Department of Academic Radiology, Beaumont Hospital, Dublin 9, Ireland.
| | - D Valenti
- Department of Radiology, McGill University, 354 Beaconsfield Blvd, Montreal, QC, H9W4A9, Canada.
| | - M A de Gregorio
- Department of Interventional Radiology, University of Zaragoza, Gomez Laguna, 13, 5° B, 50009, Saragossa, Spain.
| | - J Minocha
- Department of Radiology, University of Illinois Hospital & Health Sciences System, 1740 West Taylor Street, Suite 2483, Chicago, IL, 60612, USA.
| | - U Rimon
- Department of Diagnostic Radiology, Sheba Medical Center, 52621, Telhasomer, Israel.
| | - O Pellerin
- Department of Interventional Radiology, Université Paris 5 René Descartes, Hopital Européen Georges, Pompidou, 20 rue Leblanc, 75908, Paris, France.
| |
Collapse
|